☰

Justine M. Kane, Ph.D. - Publications

Affiliations: 
2009 University of Illinois at Chicago, Chicago, IL, United States 
Area:
Curriculum and Instruction Education, Elementary Education, Sciences Education, Developmental Psychology
Tree Info Grants Similar researchers PubMed Report error

10/500 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Varelas M, Menig E, Wilson A, Kane J. Intermingling of identities: a Black student in a middle-school science class Cultural Studies of Science Education. 1-28. DOI: 10.1007/S11422-019-09966-3  0.696
2016 Kane JM. Young African American boys narrating identities in science Journal of Research in Science Teaching. 53: 95-118. DOI: 10.1002/Tea.21247  0.485
2015 Kane JM. The structure-agency dialectic in contested science spaces: "do earthworms eat apples?" Journal of Research in Science Teaching. 52: 461-473. DOI: 10.1002/Tea.21206  0.448
2013 Varelas M, Martin DB, Kane JM. Content learning and identity construction: A framework to strengthen African American Students' mathematics and science learning in Urban Elementary Schools Human Development. 55: 319-339. DOI: 10.1159/000345324  0.695
2012 Bell P, Tzou C, Bricker L, Baines AD, Nasir NS, Snyder CR, Shah N, Ross KM, Bang M, Warren B, Rosebery AS, Medin D, Varelas M, Martin DB, Kane JM, et al. Contents Vol. 55, 2012 Human Development. 55. DOI: 10.1159/000346212  0.628
2012 Varelas M, Kane JM, Wylie CD. Young Black Children and Science: Chronotopes of Narratives around Their Science Journals. Journal of Research in Science Teaching. 49: 568-596. DOI: 10.1002/Tea.21013  0.719
2012 Kane JM. Young African American children constructing academic and disciplinary identities in an urban science classroom Science Education. 96: 457-487. DOI: 10.1002/Sce.20483  0.491
2011 Varelas M, Kane JM, Wylie CD. Young African American Children's Representations of Self, Science, and School: Making Sense of Difference. Science Education. 95: 824-851. DOI: 10.1002/Sce.20447  0.726
2010 Varelas M, Pappas CC, Tucker-Raymond E, Kane J, Hankes J, Ortiz I, Keblawe-Shamah N. Drama activities as ideational resources for primary-grade children in urban science classrooms Journal of Research in Science Teaching. 47: 302-325. DOI: 10.1002/Tea.20336  0.721
2008 Varelas M, Pappas CC, Kane JM, Arsenault A, Hankes J, Cowan BM. Urban primary-grade children think and talk science: Curricular and instructional practices that nurture participation and argumentation Science Education. 92: 65-95. DOI: 10.1002/Sce.20232  0.711
Low-probability matches (unlikely to be authored by this person)
2008 Correll CU, Kane JM. One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review. Journal of Child and Adolescent Psychopharmacology. 17: 647-56. PMID 17979584 DOI: 10.1089/CAP.2006.0117  0.191
2017 Birnbaum ML, Ernala SK, Rizvi AF, De Choudhury M, Kane JM. A Collaborative Approach to Identifying Social Media Markers of Schizophrenia by Employing Machine Learning and Clinical Appraisals. Journal of Medical Internet Research. 19: e289. PMID 28807891 DOI: 10.2196/jmir.7956  0.174
2016 Correll CU, Citrome L, Haddad PM, Lauriello J, Olfson M, Calloway SM, Kane JM. The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence. The Journal of Clinical Psychiatry. 77: 1-24. PMID 27732772 DOI: 10.4088/JCP.15032su1  0.174
1991 Szymanski S, Kane JM, Lieberman JA. A selective review of biological markers in schizophrenia Schizophrenia Bulletin. 17: 99-111. PMID 1675484 DOI: 10.1093/Schbul/17.1.99  0.173
2005 Andreasen NC, Carpenter WT, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. The American Journal of Psychiatry. 162: 441-9. PMID 15741458 DOI: 10.1176/appi.ajp.162.3.441  0.166
1991 Kane JM. Obstacles to clinical research and new drug development in schizophrenia. Schizophrenia Bulletin. 17: 353-6. PMID 1679256 DOI: 10.1093/SCHBUL/17.2.353  0.164
2011 Kane JM, Correll CU. Performance improvement CME: managing schizophrenia. The Journal of Clinical Psychiatry. 72: e31. PMID 22075104 DOI: 10.4088/JCP.9101pi7c  0.164
2013 Kolitsopoulos FM, Strom BL, Faich G, Eng SM, Kane JM, Reynolds RF. Lessons learned in the conduct of a global, large simple trial of treatments indicated for schizophrenia. Contemporary Clinical Trials. 34: 239-47. PMID 23246610 DOI: 10.1016/J.Cct.2012.12.001  0.163
2006 Bilder RM, Reiter G, Bates J, Lencz T, Szeszko P, Goldman RS, Robinson D, Lieberman JA, Kane JM. Cognitive development in schizophrenia: follow-back from the first episode. Journal of Clinical and Experimental Neuropsychology. 28: 270-82. PMID 16484098 DOI: 10.1080/13803390500360554  0.161
2018 Dixon LB, Goldman H, Srihari VH, Kane JM. Transforming the Treatment of Schizophrenia in the United States: The RAISE Initiative. Annual Review of Clinical Psychology. PMID 29328779 DOI: 10.1146/annurev-clinpsy-050817-084934  0.16
2017 Fulford D, Piskulic D, Addington J, Kane JM, Schooler NR, Mueser KT. Prospective Relationships Between Motivation and Functioning in Recovery After a First Episode of Schizophrenia. Schizophrenia Bulletin. PMID 28981811 DOI: 10.1093/Schbul/Sbx096  0.159
2002 Marder SR, Essock SM, Miller AL, Buchanan RW, Davis JM, Kane JM, Lieberman J, Schooler NR. The Mount Sinai Conference on the Pharmacotherapy of Schizophrenia Schizophrenia Bulletin. 28: 5-16. PMID 12047022 DOI: 10.1093/Oxfordjournals.Schbul.A006926  0.158
2003 Keith SJ, Kane JM. Partial Compliance and Patient Consequences in Schizophrenia: Our Patients Can Do Better Journal of Clinical Psychiatry. 64: 1308-1315. PMID 14658944 DOI: 10.4088/JCP.V64N1105  0.158
2011 Manu P, Figen V, Harris J, Kane J, Correll C. FC13-10 - Frequency of prolonged qtc in children and adolescents hospitalized for psychiatric disorders: a nested case-control study European Psychiatry. 26: 1891-1891. DOI: 10.1016/S0924-9338(11)73595-7  0.157
2017 Ernala SK, Rizvi AF, Birnbaum ML, Kane JM, De Choudhury M. Linguistic Markers Indicating Therapeutic Outcomes of Social Media Disclosures of Schizophrenia Proceedings of the Acm On Human-Computer Interaction. 1: 1-27. DOI: 10.1145/3134678  0.157
2010 Kane JM, Correll CU. Past and present progress in the pharmacologic treatment of schizophrenia. The Journal of Clinical Psychiatry. 71: 1115-24. PMID 20923620 DOI: 10.4088/JCP.10r06264yel  0.156
1991 Kane JM. New developments in the pharmacologic treatment of schizophrenia: editor's introduction. Schizophrenia Bulletin. 17: 193-5. PMID 1679250 DOI: 10.1093/SCHBUL/17.2.193  0.155
2019 Buck B, Scherer E, Brian R, Wang R, Wang W, Campbell A, Choudhury T, Hauser M, Kane JM, Ben-Zeev D. Relationships between smartphone social behavior and relapse in schizophrenia: A preliminary report. Schizophrenia Research. PMID 30940400 DOI: 10.1016/j.schres.2019.03.014  0.153
2016 Rosenheck R, Mueser KT, Sint K, Lin H, Lynde DW, Glynn SM, Robinson DG, Schooler NR, Marcy P, Mohamed S, Kane JM. Supported employment and education in comprehensive, integrated care for first episode psychosis: Effects on work, school, and disability income. Schizophrenia Research. PMID 27667369 DOI: 10.1016/J.Schres.2016.09.024  0.153
2015 Robinson DG, Schooler NR, John M, Correll CU, Marcy P, Addington J, Brunette MF, Estroff SE, Mueser KT, Penn D, Robinson J, Rosenheck RA, Severe J, Goldstein A, Azrin S, ... ... Kane JM, et al. Prescription practices in the treatment of first-episode schizophrenia spectrum disorders: data from the national RAISE-ETP study. The American Journal of Psychiatry. 172: 237-48. PMID 25727536 DOI: 10.1176/Appi.Ajp.2014.13101355  0.153
2001 Cornblatt BA, Lencz T, Kane JM. Treatment of the schizophrenia prodrome: is it presently ethical? Schizophrenia Research. 51: 31-8. PMID 11479063 DOI: 10.1016/S0920-9964(01)00236-5  0.153
2021 Harvey PD, Kane JM. Addressing Patients' Unmet Needs to Improve Outcomes in Schizophrenia. The Journal of Clinical Psychiatry. 82. PMID 34004086 DOI: 10.4088/JCP.IC20018AH3C  0.153
2017 Sarpal DK, Robinson DG, Fales C, Lencz T, Argyelan M, Karlsgodt KH, Gallego JA, John M, Kane JM, Szeszko PR, Malhotra AK. Relationship between Duration of Untreated Psychosis and Intrinsic Corticostriatal Connectivity in Patients with Early Phase Schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 28294137 DOI: 10.1038/npp.2017.55  0.152
2011 Correll CU, Lops JD, Figen V, Malhotra AK, Kane JM, Manu P. QT interval duration and dispersion in children and adolescents treated with ziprasidone. The Journal of Clinical Psychiatry. 72: 854-60. PMID 21457682 DOI: 10.4088/JCP.10m05990yel  0.151
2011 Correll CU, Kishimoto T, Nielsen J, Kane JM. Quantifying clinical relevance in the treatment of schizophrenia. Clinical Therapeutics. 33: B16-39. PMID 22177377 DOI: 10.1016/j.clinthera.2011.11.016  0.151
2015 Kane JM, Correll CU. Making the Link Between Science and Symptoms in Schizophrenia The Journal of Clinical Psychiatry. 76: e15-e15. DOI: 10.4088/JCP.13078VI1C  0.151
2013 Kane JM, Kishimoto T, Correll CU. Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. Journal of Clinical Epidemiology. 66: S37-41. PMID 23849151 DOI: 10.1016/j.jclinepi.2013.01.012  0.148
2008 Strom BL, Faich GA, Reynolds RF, Eng SM, D'Agostino RB, Ruskin JN, Kane JM. The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC): design and baseline subject characteristics. The Journal of Clinical Psychiatry. 69: 114-21. PMID 18312045 DOI: 10.4088/Jcp.V69N0115  0.147
2013 Stentebjerg-Olesen M, Jeppesen P, Pagsberg AK, Fink-Jensen A, Kapoor S, Chekuri R, Carbon M, Al-Jadiri A, Kishimoto T, Kane JM, Correll CU. Early nonresponse determined by the clinical global impressions scale predicts poorer outcomes in youth with schizophrenia spectrum disorders naturalistically treated with second-generation antipsychotics. Journal of Child and Adolescent Psychopharmacology. 23: 665-75. PMID 24266529 DOI: 10.1089/Cap.2013.0007  0.147
2020 Schoretsanitis G, Kane JM, Correll CU, Marder SR, Citrome L, Newcomer JW, Robinson DG, Goff DC, Kelly DL, Freudenreich O, Piacentino D, Paulzen M, Conca A, Zernig G, Haen E, et al. Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice: A Joint Consensus Statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie. The Journal of Clinical Psychiatry. 81. PMID 32433836 DOI: 10.4088/Jcp.19Cs13169  0.147
1993 Kane JM, Marder SR. Psychopharmacologic treatment of schizophrenia. Schizophrenia Bulletin. 19: 287-302. PMID 8100642 DOI: 10.1093/SCHBUL/19.2.287  0.146
2019 Kane JM, Agid O, Baldwin ML, Howes O, Lindenmayer JP, Marder S, Olfson M, Potkin SG, Correll CU. Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia. The Journal of Clinical Psychiatry. 80. PMID 30840788 DOI: 10.4088/Jcp.18Com12123  0.146
2003 Woerner MG, Robinson DG, Alvir JM, Sheitman BB, Lieberman JA, Kane JM. Clozapine as a first treatment for schizophrenia. The American Journal of Psychiatry. 160: 1514-6. PMID 12900316 DOI: 10.1176/Appi.Ajp.160.8.1514  0.146
2001 Kane JM, Marder SR, Schooler NR, Wirshing WC, Umbricht D, Baker RW, Wirshing DA, Safferman A, Ganguli R, McMeniman M, Borenstein M. Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Archives of General Psychiatry. 58: 965-72. PMID 11576036 DOI: 10.1001/ARCHPSYC.58.10.965  0.146
2014 Birnbaum ML, Candan K, Libby I, Pascucci O, Kane J. Impact of online resources and social media on help-seeking behaviour in youth with psychotic symptoms. Early Intervention in Psychiatry. PMID 25200743 DOI: 10.1111/eip.12179  0.145
2008 Shen J, Kobak KA, Zhao Y, Alexander MM, Kane JM. Use of remote centralized raters via live 2-way video in a multicenter clinical trial for schizophrenia. Journal of Clinical Psychopharmacology. 28: 691-3. PMID 19011439 DOI: 10.1097/JCP.0b013e31818c9ba3  0.145
2009 Kane JM, Kim E, Kan HJ, Guo Z, Bates JA, Whitehead R, Pikalov A. Comparative utility of aripiprazole and haloperidol in schizophrenia: post hoc analysis of two 52-week, randomized, controlled trials. Applied Health Economics and Health Policy. 7: 109-19. PMID 19731968 DOI: 10.1007/BF03256145  0.144
2019 Kane JM, Correll CU. Optimizing Treatment Choices to Improve Adherence and Outcomes in Schizophrenia. The Journal of Clinical Psychiatry. 80. PMID 31536686 DOI: 10.4088/JCP.IN18031AH1C  0.144
2008 Keefe RS, Malhotra AK, Meltzer HY, Kane JM, Buchanan RW, Murthy A, Sovel M, Li C, Goldman R. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 33: 1217-28. PMID 17625502 DOI: 10.1038/Sj.Npp.1301499  0.143
1991 Safferman A, Lieberman JA, Kane JM, Szymanski S, Kinon B. Update on the clinical efficacy and side effects of clozapine. Schizophrenia Bulletin. 17: 247-61. PMID 1882209 DOI: 10.1093/Schbul/17.2.247  0.143
2008 Szeszko PR, Robinson DG, Ashtari M, Vogel J, Betensky J, Sevy S, Ardekani BA, Lencz T, Malhotra AK, McCormack J, Miller R, Lim KO, Gunduz-Bruce H, Kane JM, Bilder RM. Clinical and neuropsychological correlates of white matter abnormalities in recent onset schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 33: 976-84. PMID 17581532 DOI: 10.1038/sj.npp.1301480  0.143
2009 Kane JM, Correll CU, Goff DC, Kirkpatrick B, Marder SR, Vester-Blokland E, Sun W, Carson WH, Pikalov A, Assunção-Talbott S. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. The Journal of Clinical Psychiatry. 70: 1348-57. PMID 19906340 DOI: 10.4088/Jcp.09M05154Yel  0.143
2020 Susanne Neumeier M, Winkelbeiner S, Kane J, Seifritz E, Huhn M, Leucht S, Homan P. T216. VARIATION IN SIDE EFFECTS TO ANTIPSYCHOTIC TREATMENT ACROSS SCHIZOPHRENIA SPECTRUM DISORDERS Schizophrenia Bulletin. 46: S314-S315. DOI: 10.1093/schbul/sbaa029.776  0.143
1997 Kane JM, Tamminga CA. Sertindole (Serdolect): preclinical and clinical findings of a new atypical antipsychotic Expert Opinion On Investigational Drugs. 6: 1729-1741. PMID 15989577 DOI: 10.1517/13543784.6.11.1729  0.142
1996 Umbricht D, Kane JM. Risperidone: efficacy and safety. Schizophrenia Bulletin. 21: 593-606. PMID 8749887 DOI: 10.1093/SCHBUL/21.4.593  0.141
2016 Schooler NR, Marder SR, Chengappa KN, Petrides G, Ames D, Wirshing WC, McMeniman M, Baker RW, Parepally H, Umbricht D, Kane JM. Clozapine and risperidone in moderately refractory schizophrenia: a 6-month randomized double-blind comparison. The Journal of Clinical Psychiatry. PMID 27035871 DOI: 10.4088/JCP.13m08351  0.141
2015 Kahn RS, Sommer IE, Murray RM, Meyer-Lindenberg A, Weinberger DR, Cannon TD, O'Donovan M, Correll CU, Kane JM, van Os J, Insel TR. Schizophrenia. Nature Reviews. Disease Primers. 1: 15067. PMID 27189524 DOI: 10.1038/nrdp.2015.67  0.14
2020 Birnbaum ML, Norel R, Van Meter A, Ali AF, Arenare E, Eyigoz E, Agurto C, Germano N, Kane JM, Cecchi GA. Identifying signals associated with psychiatric illness utilizing language and images posted to Facebook. Npj Schizophrenia. 6: 38. PMID 33273468 DOI: 10.1038/s41537-020-00125-0  0.14
2020 Tseng VW, Sano A, Ben-Zeev D, Brian R, Campbell AT, Hauser M, Kane JM, Scherer EA, Wang R, Wang W, Wen H, Choudhury T. Using behavioral rhythms and multi-task learning to predict fine-grained symptoms of schizophrenia. Scientific Reports. 10: 15100. PMID 32934246 DOI: 10.1038/s41598-020-71689-1  0.14
2018 Birnbaum ML, Rizvi AF, Faber K, Addington J, Correll CU, Gerber C, Lahti AC, Loewy RL, Mathalon DH, Nelson LA, Voineskos AN, Walker EF, Ward E, Kane JM. Digital Trajectories to Care in First-Episode Psychosis. Psychiatric Services (Washington, D.C.). appips201800180. PMID 30256181 DOI: 10.1176/Appi.Ps.201800180  0.14
2013 Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. The Journal of Clinical Psychiatry. 74: 957-65. PMID 24229745 DOI: 10.4088/JCP.13r08440  0.14
2016 Rubio J, Inczedy-Farkas G, Leucht S, Kane J, Correll C. Mega-review of meta-analyses investigating the short-term efficacy of pharmacologic augmentation strategies of antipsychotics in patients with schizophrenia European Psychiatry. 33: S550-S551. DOI: 10.1016/j.eurpsy.2016.01.2032  0.139
2010 Kane JM, D'Souza DC, Patkar AA, Youakim JM, Tiller JM, Yang R, Keefe RS. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study. The Journal of Clinical Psychiatry. 71: 1475-81. PMID 20816042 DOI: 10.4088/JCP.09m05950gry  0.139
2015 Kane JM, Schooler NR, Marcy P, Correll CU, Brunette MF, Mueser KT, Rosenheck RA, Addington J, Estroff SE, Robinson J, Penn DL, Robinson DG. The RAISE early treatment program for first-episode psychosis: background, rationale, and study design. The Journal of Clinical Psychiatry. 76: 240-6. PMID 25830446 DOI: 10.4088/Jcp.14M09289  0.139
2017 Pillai A, Schooler NR, Peter D, Looney SW, Goff DC, Kopelowicz A, Lauriello J, Manschreck T, Mendelowitz A, Miller DD, Severe JB, Wilson DR, Ames D, Bustillo J, Kane JM, et al. Predicting relapse in schizophrenia: Is BDNF a plausible biological marker? Schizophrenia Research. PMID 28734907 DOI: 10.1016/J.Schres.2017.06.059  0.139
1994 Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A, Kronig M, Bookstein P, Kane JM. Clinical effects of clozapine in chronic schizophrenia: Response to treatment and predictors of outcome American Journal of Psychiatry. 151: 1744-1752. PMID 7977880 DOI: 10.1176/Ajp.151.12.1744  0.138
2007 Kane JM. Utilization of long-acting antipsychotic medication in patient care. Cns Spectrums. 11: 1-7; quiz 7-8. PMID 17146411 DOI: 10.1017/S1092852900025852  0.138
1998 Kane JM, Aguglia E, Altamura AC, Ayuso Gutierrez JL, Brunello N, Fleischhacker WW, Gaebel W, Gerlach J, Guelfi JD, Kissling W, Lapierre YD, Lindström E, Mendlewicz J, Racagni G, Carulla LS, et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 8: 55-66. PMID 9452941 DOI: 10.1016/S0924-977X(97)00045-X  0.138
2006 Cavazzoni PA, Berg PH, Kryzhanovskaya LA, Briggs SD, Roddy TE, Tohen M, Kane JM. Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials. The Journal of Clinical Psychiatry. 67: 107-13. PMID 16426096 DOI: 10.4088/JCP.V67N0116  0.138
1992 Kane JM. Clinical Efficacy of Clozapine in Treatment-Refractory Schizophrenia: An Overview British Journal of Psychiatry. 160: 41-45. DOI: 10.1192/S0007125000296918  0.138
2014 Szeszko PR, Robinson DG, Ikuta T, Peters BD, Gallego JA, Kane J, Malhotra AK. White matter changes associated with antipsychotic treatment in first-episode psychosis. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 39: 1324-31. PMID 24549105 DOI: 10.1038/npp.2013.288  0.137
2020 Potkin SG, Kane JM, Correll CU, Lindenmayer JP, Agid O, Marder SR, Olfson M, Howes OD. The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. Npj Schizophrenia. 6: 1. PMID 31911624 DOI: 10.1038/s41537-019-0090-z  0.137
2008 Kane JM, Osuntokun O, Kryzhanovskaya L, Xu W, Stauffer V, Watson S, Osuntokun O. A 28-WEEK, RANDOMIZED, DOUBLE-BLIND STUDY OF OLANZAPINE VERSUS ARIPIPRAZOLE IN THE TREATMENT OF SCHIZOPHRENIA Schizophrenia Research. 102: 265. DOI: 10.1016/S0920-9964(08)70798-9  0.137
2008 Kane JM. Teaching and practicing psychopharmacology. The Journal of Clinical Psychiatry. 68: 1807-8. PMID 18052576 DOI: 10.4088/JCP.v68n1122  0.137
2007 Kane JM, Crandall DT, Marcus RN, Eudicone J, Pikalov A, Carson WH, Swyzen W. Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks. Schizophrenia Research. 95: 143-50. PMID 17644313 DOI: 10.1016/j.schres.2007.05.009  0.136
2019 Masuda T, Misawa F, Takase M, Kane JM, Correll CU. Association With Hospitalization and All-Cause Discontinuation Among Patients With Schizophrenia on Clozapine vs Other Oral Second-Generation Antipsychotics: A Systematic Review and Meta-analysis of Cohort Studies. Jama Psychiatry. PMID 31365048 DOI: 10.1001/jamapsychiatry.2019.1702  0.136
2019 Rubio JM, Kane JM. How and when to use clozapine. Acta Psychiatrica Scandinavica. PMID 31603988 DOI: 10.1111/acps.13111  0.136
1987 Kane JM. Treatment of schizophrenia. Schizophrenia Bulletin. 13: 133-56. PMID 2885912 DOI: 10.1093/SCHBUL/13.1.133  0.136
2017 Ismail Z, Peters-Strickland T, Miguelez M, Baker RA, Hertel P, Eramo A, Jin N, Perry P, Sanchez R, McQuade RD, Kane JM. Aripiprazole Once-Monthly in the Treatment of Acute Psychotic Episodes in Schizophrenia: Post Hoc Analysis of Positive and Negative Syndrome Scale Marder Factor Scores. Journal of Clinical Psychopharmacology. PMID 28383362 DOI: 10.1097/Jcp.0000000000000710  0.135
2002 Chong SA, Mahendran R, Machin D, Chua HC, Parker G, Kane J. Tardive dyskinesia among Chinese and Malay patients with schizophrenia. Journal of Clinical Psychopharmacology. 22: 26-30. PMID 11799339 DOI: 10.1097/00004714-200202000-00005  0.135
2015 Li Q, Xiang YT, Su YA, Shu L, Yu X, Correll CU, Ungvari GS, Chiu HF, Ma C, Wang GH, Bai PS, Li T, Sun LZ, Shi JG, Chen XS, ... ... Kane JM, et al. Clozapine in schizophrenia and its association with treatment satisfaction and quality of life: Findings of the three national surveys on use of psychotropic medications in China (2002-2012). Schizophrenia Research. PMID 26277534 DOI: 10.1016/j.schres.2015.07.048  0.135
1993 Kane JM. New developments in the pharmacologic treatment of schizophrenia Journal of Psychiatric Research. 27: 349-353. DOI: 10.1016/0022-3956(93)90061-6  0.135
2013 Kishi T, Fujita K, Furukawa O, Suzuki T, Moriwaki M, Nitta M, Hattori M, Tsunoka T, Chekuri R, Kane JM, Correll CU, Iwata N. Efficacy and tolerability of clozapine in Japanese patients with treatment-resistant schizophrenia: results from a 12-week, flexible dose study using raters masked to antipsychotic choice. Asian Journal of Psychiatry. 6: 200-7. PMID 23642976 DOI: 10.1016/j.ajp.2012.10.007  0.135
2019 Kishimoto T, Hagi K, Nitta M, Kane JM, Correll CU. Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons. World Psychiatry : Official Journal of the World Psychiatric Association (Wpa). 18: 208-224. PMID 31059621 DOI: 10.1002/wps.20632  0.135
2008 Kane JM. Relapse prevention in patients with schizophrenia. The Journal of Clinical Psychiatry. 69: e11. PMID 18507484 DOI: 10.4088/jcp.0408e11  0.135
1989 Kane JM, Mayerhoff D. Do Negative Symptoms Respond to Pharmacological Treatment? British Journal of Psychiatry. 155: 115-118. DOI: 10.1192/S0007125000291630  0.134
2020 Jonas KG, Fochtmann LJ, Perlman G, Tian Y, Kane JM, Bromet EJ, Kotov R. Lead-Time Bias Confounds Association Between Duration of Untreated Psychosis and Illness Course in Schizophrenia. The American Journal of Psychiatry. appiajp201919030324. PMID 32046533 DOI: 10.1176/Appi.Ajp.2019.19030324  0.134
1984 Kane JM. Low dose medication strategies in the maintenance treatment of schizophrenia. Schizophrenia Bulletin. 9: 528-32. PMID 6140751 DOI: 10.1093/SCHBUL/9.4.528  0.134
1997 Fenton WS, Kane JM. Clinical challenges in the psychopharmacology of schizophrenia. Schizophrenia Bulletin. 23: 563-5. PMID 9365995 DOI: 10.1093/SCHBUL/23.4.563  0.134
2007 Goldberg TE, Goldman RS, Burdick KE, Malhotra AK, Lencz T, Patel RC, Woerner MG, Schooler NR, Kane JM, Robinson DG. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Archives of General Psychiatry. 64: 1115-22. PMID 17909123 DOI: 10.1001/Archpsyc.64.10.1115  0.133
2020 Wagner E, Kane JM, Correll CU, Howes O, Siskind D, Honer WG, Lee J, Falkai P, Schneider-Axmann T, Hasan A. Clozapine Combination and Augmentation Strategies in Patients With Schizophrenia -Recommendations From an International Expert Survey Among the Treatment Response and Resistance in Psychosis (TRRIP) Working Group. Schizophrenia Bulletin. PMID 32421188 DOI: 10.1093/Schbul/Sbaa060  0.133
2019 Brown HE, Freudenreich O, Fan X, Heard SO, Goff D, Petrides G, Harrington AL, Kane JM, Judge H, Hoeppner B, Fava M, Perlis RH. Efficacy and Tolerability of Adjunctive Intravenous Sodium Nitroprusside Treatment for Outpatients With Schizophrenia: A Randomized Clinical Trial. Jama Psychiatry. PMID 30916714 DOI: 10.1001/Jamapsychiatry.2019.0151  0.133
2020 Birnbaum ML, Wen H, Van Meter A, Ernala SK, Rizvi AF, Arenare E, Estrin D, De Choudhury M, Kane JM. Identifying emerging mental illness utilizing search engine activity: A feasibility study. Plos One. 15: e0240820. PMID 33064759 DOI: 10.1371/journal.pone.0240820  0.133
2007 Helldin L, Kane JM, Karilampi U, Norlander T, Archer T. Remission in prognosis of functional outcome: a new dimension in the treatment of patients with psychotic disorders. Schizophrenia Research. 93: 160-8. PMID 17395430 DOI: 10.1016/j.schres.2007.01.014  0.133
2015 Lieberman JA, Davis RE, Correll CU, Goff DC, Kane JM, Tamminga CA, Mates S, Vanover KE. ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial. Biological Psychiatry. PMID 26444072 DOI: 10.1016/J.Biopsych.2015.08.026  0.133
2017 Earley W, Durgam S, Lu K, Laszlovszky I, Debelle M, Kane JM. Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies. International Clinical Psychopharmacology. PMID 28692485 DOI: 10.1097/YIC.0000000000000187  0.132
1995 Szymanski S, Lieberman JA, Alvir JM, Mayerhoff D, Loebel A, Geisler S, Chakos M, Koreen A, Jody D, Kane J, Woerner M, Cooper T. Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients American Journal of Psychiatry. 152: 698-703. PMID 7726309 DOI: 10.1176/Ajp.152.5.698  0.132
2009 Kane JM, Assunção-Talbott S, Eudicone JM, Pikalov A, Whitehead R, Crandall DT. Corrigendum to “The efficacy of aripiprazole in the treatment of multiple symptom domains in patients with acute schizophrenia: A pooled analysis of data from the pivotal trials” [Schizophrenia Research 105 (2008) 208–215] Schizophrenia Research. 107: 334-335. DOI: 10.1016/j.schres.2008.10.012  0.132
1997 Carpenter WT, Schooler NR, Kane JM. The rationale and ethics of medication-free research in schizophrenia. Archives of General Psychiatry. 54: 401-7. PMID 9152092 DOI: 10.1001/ARCHPSYC.1997.01830170015002  0.132
2017 Nagendra A, Schooler NR, Kane JM, Robinson DG, Mueser KT, Estroff SE, Addington J, Marcy P, Penn DL. Demographic, psychosocial, clinical, and neurocognitive baseline characteristics of Black Americans in the RAISE-ETP study. Schizophrenia Research. PMID 28709773 DOI: 10.1016/J.Schres.2017.06.038  0.132
1991 Lieberman JA, Saltz BL, Johns CA, Pollack S, Borenstein M, Kane J. The effects of clozapine on tardive dyskinesia. The British Journal of Psychiatry : the Journal of Mental Science. 158: 503-10. PMID 1675900 DOI: 10.1192/Bjp.158.4.503  0.132
2005 Burdick KE, Hodgkinson CA, Szeszko PR, Lencz T, Ekholm JM, Kane JM, Goldman D, Malhotra AK. DISC1 and neurocognitive function in schizophrenia. Neuroreport. 16: 1399-402. PMID 16056147 DOI: 10.1097/01.Wnr.0000175248.25535.F6  0.132
1987 Lieberman JA, Kane JM, Sarantakos S, Gadaleta D, Woerner M, Alvir J, Ramos-Lorenzi J. Prediction of relapse in schizophrenia. Archives of General Psychiatry. 44: 597-603. PMID 2886110 DOI: 10.1001/Archpsyc.1987.01800190013002  0.131
2013 Baker R, Carson W, Perry P, Sanchez R, Jin N, McQuade R, Kane J, Fleischhacker W. 2281 – Psychosocial and overall effectiveness of aripiprazole once-monthly vs. placebo once-monthly for maintenance treatment in schizophrenia European Psychiatry. 28: 1. DOI: 10.1016/S0924-9338(13)77141-4  0.131
2021 Rubio JM, Taipale H, Tanskanen A, Correll CU, Kane JM, Tiihonen J. Long-term Continuity of Antipsychotic Treatment for Schizophrenia: A Nationwide Study. Schizophrenia Bulletin. PMID 34129663 DOI: 10.1093/schbul/sbab063  0.131
2011 Correll CU, Harris J, Figen V, Kane JM, Manu P. Antipsychotic drug administration does not correlate with prolonged rate-corrected QT interval in children and adolescents: results from a nested case-control study. Journal of Child and Adolescent Psychopharmacology. 21: 365-8. PMID 21823910 DOI: 10.1089/cap.2011.0024  0.131
2012 Kane JM, Yang R, Youakim JM. Adjunctive armodafinil for negative symptoms in adults with schizophrenia: a double-blind, placebo-controlled study. Schizophrenia Research. 135: 116-22. PMID 22178084 DOI: 10.1016/j.schres.2011.11.006  0.131
2019 Winkelbeiner S, Leucht S, Kane JM, Homan P. Evaluation of Differences in Individual Treatment Response in Schizophrenia Spectrum Disorders: A Meta-analysis. Jama Psychiatry. PMID 31158853 DOI: 10.1001/jamapsychiatry.2019.1530  0.131
2015 Loebel A, Citrome L, Correll CU, Xu J, Cucchiaro J, Kane JM. Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalation. Bmc Psychiatry. 15: 271. PMID 26521019 DOI: 10.1186/s12888-015-0629-0  0.131
2014 Kane JM, Peters-Strickland T, Baker RA, Hertel P, Eramo A, Jin N, Perry PP, Gara M, McQuade RD, Carson WH, Sanchez R. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study. The Journal of Clinical Psychiatry. 75: 1254-60. PMID 25188501 DOI: 10.4088/Jcp.14M09168  0.131
2017 Browne J, Penn DL, Bauer DJ, Meyer-Kalos P, Mueser KT, Robinson DG, Addington J, Schooler NR, Glynn SM, Gingerich S, Marcy P, Kane JM. Perceived Autonomy Support in the NIMH RAISE Early Treatment Program. Psychiatric Services (Washington, D.C.). appips201600480. PMID 28566027 DOI: 10.1176/Appi.Ps.201600480  0.131
2009 Masand PS, Roca M, Turner MS, Kane JM. Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review. Primary Care Companion to the Journal of Clinical Psychiatry. 11: 147-54. PMID 19750066 DOI: 10.4088/PCC.08r00612  0.13
2015 Robinson DG, Gallego JA, John M, Petrides G, Hassoun Y, Zhang JP, Lopez L, Braga RJ, Sevy SM, Addington J, Kellner CH, Tohen M, Naraine M, Bennett N, Greenberg J, ... ... Kane JM, et al. A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes. Schizophrenia Bulletin. PMID 26338693 DOI: 10.1093/Schbul/Sbv125  0.13
2018 Correll CU, Rubio JM, Kane JM. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry : Official Journal of the World Psychiatric Association (Wpa). 17: 149-160. PMID 29856543 DOI: 10.1002/wps.20516  0.13
1997 Kane J. Broadening perspective in the treatment of schizophrenia Biological Psychiatry. 42: 62S. DOI: 10.1016/S0006-3223(97)87132-6  0.13
1984 Lieberman JA, Kane JM, Gadaleta D, Brenner R, Lesser MS, Kinon B. Methylphenidate challenge as a predictor of relapse in schizophrenia. The American Journal of Psychiatry. 141: 633-8. PMID 6143506 DOI: 10.1176/AJP.141.5.633  0.13
2010 Burdick KE, DeRosse P, Kane JM, Lencz T, Malhotra AK. Association of genetic variation in the MET proto-oncogene with schizophrenia and general cognitive ability. The American Journal of Psychiatry. 167: 436-43. PMID 20080979 DOI: 10.1176/Appi.Ajp.2009.09050615  0.13
2007 Kane JM. Schizophrenia International Research Society. Schizophrenia Bulletin. 33: 1259. PMID 17890763 DOI: 10.1093/SCHBUL/SBM102  0.13
2015 Vernal DL, Kapoor S, Al-Jadiri A, Sheridan EM, Borenstein Y, Mormando C, David L, Singh S, Seidman AJ, Carbon M, Gerstenberg M, Saito E, Kane JM, Steinhausen HC, Correll CU. Outcome of Youth with Early-Phase Schizophrenia-Spectrum Disorders and Psychosis Not Otherwise Specified Treated with Second-Generation Antipsychotics: 12 Week Results from a Prospective, Naturalistic Cohort Study. Journal of Child and Adolescent Psychopharmacology. 25: 535-47. PMID 26375767 DOI: 10.1089/cap.2014.0164  0.13
2010 Strom BL, Eng SM, Faich G, Reynolds RF, D'Agostino RB, Ruskin J, Kane JM, Geier J, Karayal ON, Kremer C. THE ZIPRASIDONE OBSERVATIONAL STUDY OF CARDIAC OUTCOMES (ZODIAC): FINDINGS FROM A LARGE SIMPLE TRIAL OF ZIPRASIDONE VS. OLANZAPINE IN REAL-WORLD USE AMONG 18154 PATIENTS WITH SCHIZOPHRENIA Schizophrenia Research. 117: 311. DOI: 10.1016/J.Schres.2010.02.523  0.129
2013 Evins AE, Green AI, Kane JM, Murray RM. Does using marijuana increase the risk for developing schizophrenia? The Journal of Clinical Psychiatry. 74: e08. PMID 23656852 DOI: 10.4088/Jcp.12012Tx2C  0.129
2015 Weiss SL, Fitzgerald JC, Maffei FA, Kane JM, Rodriguez-Nunez A, Hsing DD, Franzon D, Kee SY, Bush JL, Roy JA, Thomas NJ, Nadkarni VM. Discordant identification of pediatric severe sepsis by research and clinical definitions in the SPROUT international point prevalence study. Critical Care (London, England). 19: 325. PMID 26373923 DOI: 10.1186/S13054-015-1055-X  0.129
2011 Case M, Stauffer VL, Ascher-Svanum H, Conley R, Kapur S, Kane JM, Kollack-Walker S, Jacob J, Kinon BJ. The heterogeneity of antipsychotic response in the treatment of schizophrenia. Psychological Medicine. 41: 1291-300. PMID 20925971 DOI: 10.1017/S0033291710001893  0.129
2015 Kane JM, Sanchez R, Baker RA, Eramo A, Peters-Strickland T, Perry PP, Johnson BR, Tsai LF, Carson WH, McQuade RD, Fleischhacker WW. Patient-Centered Outcomes with Aripiprazole Once-Monthly for Maintenance Treatment in Patients with Schizophrenia: Results From Two Multicenter, Randomized, Double-Blind Studies. Clinical Schizophrenia & Related Psychoses. 9: 79-87. PMID 25711509 DOI: 10.3371/Csrp.Kasa.022015  0.129
2007 Leucht S, Busch R, Kissling W, Kane JM. Early prediction of antipsychotic nonresponse among patients with schizophrenia. The Journal of Clinical Psychiatry. 68: 352-60. PMID 17388703 DOI: 10.4088/JCP.V68N0301  0.129
2010 Kane JM, Detke HC, Naber D, Sethuraman G, Lin DY, Bergstrom RF, McDonnell D. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. The American Journal of Psychiatry. 167: 181-9. PMID 20008947 DOI: 10.1176/appi.ajp.2009.07081221  0.129
2016 Baumel A, Pawar A, Kane JM, Correll CU. Digital Parent Training for Children with Disruptive Behaviors: Systematic Review and Meta-Analysis of Randomized Trials. Journal of Child and Adolescent Psychopharmacology. PMID 27286325 DOI: 10.1089/cap.2016.0048  0.129
2017 Sarpal D, Robinson D, Fales C, Lencz T, Argyelan M, Karlsgodt K, Gallego J, John M, Kane J, Szeszko P, Malhotra A. 81. Relationship Between Untreated Psychosis and Intrinsic Corticostriatal Connectivity in Patients With Recent-Onset Schizophrenia Schizophrenia Bulletin. 43: S45-S46. DOI: 10.1093/schbul/sbx021.120  0.129
2005 Robinson DG, Woerner MG, Delman HM, Kane JM. Pharmacological treatments for first-episode schizophrenia. Schizophrenia Bulletin. 31: 705-22. PMID 16006592 DOI: 10.1093/SCHBUL/SBI032  0.129
2011 Ascher-Svanum H, Stensland MD, Peng X, Faries DE, Stauffer VL, Osuntokun OO, Kane JM. Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia. Current Medical Research and Opinion. 27: 115-22. PMID 21110749 DOI: 10.1185/03007995.2010.537594  0.129
2015 Sarpal DK, Robinson DG, Lencz T, Argyelan M, Ikuta T, Karlsgodt K, Gallego JA, Kane JM, Szeszko PR, Malhotra AK. Antipsychotic treatment and functional connectivity of the striatum in first-episode schizophrenia. Jama Psychiatry. 72: 5-13. PMID 25372846 DOI: 10.1001/jamapsychiatry.2014.1734  0.129
2012 Kane JM, Sanchez R, Perry PP, Jin N, Johnson BR, Forbes RA, McQuade RD, Carson WH, Fleischhacker WW. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. The Journal of Clinical Psychiatry. 73: 617-24. PMID 22697189 DOI: 10.4088/JCP.11m07530  0.129
2008 Correll CU, Kane J, Goff D, Kirkpatrick B, Marder SR, Vester-Blokland E, Sun W, Pikalov A, Assunção-Talbott S. Aripiprazole In Combination With Risperidone Or Quetiapine: Results From A 16-Week, Randomized, Double-Blind Study In Subjects With Schizophrenia Schizophrenia Research. 102: 254. DOI: 10.1016/S0920-9964(08)70764-3  0.128
2006 Robinson DG, Woerner MG, Napolitano B, Patel RC, Sevy SM, Gunduz-Bruce H, Soto-Perello JM, Mendelowitz A, Khadivi A, Miller R, McCormack J, Lorell BS, Lesser ML, Schooler NR, Kane JM. Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. The American Journal of Psychiatry. 163: 2096-102. PMID 17151160 DOI: 10.1176/ajp.2006.163.12.2096  0.128
2015 Petrides G, Malur C, Braga RJ, Bailine SH, Schooler NR, Malhotra AK, Kane JM, Sanghani S, Goldberg TE, John M, Mendelowitz A. Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study. The American Journal of Psychiatry. 172: 52-8. PMID 25157964 DOI: 10.1176/appi.ajp.2014.13060787  0.128
2011 Correll CU, Shaikh L, Gallego JA, Nachbar J, Olshanskiy V, Kishimoto T, Kane JM. Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior. Schizophrenia Research. 131: 58-62. PMID 21419603 DOI: 10.1016/j.schres.2011.02.016  0.128
2002 Kane JM, Davis JM, Schooler N, Marder S, Casey D, Brauzer B, Mintz J, Conley R. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. The American Journal of Psychiatry. 159: 554-60. PMID 11925292 DOI: 10.1176/APPI.AJP.159.4.554  0.128
2010 Kane JM, Barnes TR, Correll CU, Sachs G, Buckley P, Eudicone J, McQuade R, Tran QV, Pikalov A, Assunção-Talbott S. Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials. Journal of Psychopharmacology (Oxford, England). 24: 1019-29. PMID 20008446 DOI: 10.1177/0269881109348157  0.127
2013 Nitta M, Kishimoto T, Müller N, Weiser M, Davidson M, Kane JM, Correll CU. Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. Schizophrenia Bulletin. 39: 1230-41. PMID 23720576 DOI: 10.1093/schbul/sbt070  0.127
2012 Kishimoto T, Robenzadeh A, Ng S, Watanabe K, Mimura M, Leucht C, Leucht S, Kane JM, Correll CU. Poster #208 NEW RESULTS ALTER BALANCE OF EVIDENCE IN META-ANALYSIS OF LONG-ACTING INJECTABLE VS. ORAL ANTIPSYCHOTICS IN SCHIZOPHRENIA Schizophrenia Research. 136: S166. DOI: 10.1016/S0920-9964(12)70522-4  0.127
2015 Samara MT, Leucht C, Leeflang MM, Anghelescu IG, Chung YC, Crespo-Facorro B, Elkis H, Hatta K, Giegling I, Kane JM, Kayo M, Lambert M, Lin CH, Möller HJ, Pelayo-Terán JM, et al. Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review. The American Journal of Psychiatry. 172: 617-29. PMID 26046338 DOI: 10.1176/appi.ajp.2015.14101329  0.127
2015 Kane JM, Skuban A, Ouyang J, Hobart M, Pfister S, McQuade RD, Nyilas M, Carson WH, Sanchez R, Eriksson H. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophrenia Research. 164: 127-35. PMID 25682550 DOI: 10.1016/j.schres.2015.01.038  0.127
2020 Birnbaum ML, Kulkarni PP, Van Meter A, Chen V, Rizvi AF, Arenare E, De Choudhury M, Kane JM. Utilizing Machine Learning on Internet Search Activity to Support the Diagnostic Process and Relapse Detection in Young Individuals With Early Psychosis: Feasibility Study. Jmir Mental Health. 7: e19348. PMID 32870161 DOI: 10.2196/19348  0.127
2012 Loebel A, Cucchiaro J, Xu l, Sarma K, Pikalov A, Kane JM. Poster #208 EFFECTIVENESS OF LURASIDONE VS. QUETIAPINE XR FOR RELAPSE PREVENTION IN SCHIZOPHRENIA: A 12-MONTH, DOUBLE-BLIND STUDY Schizophrenia Research. 136: S260. DOI: 10.1016/S0920-9964(12)70779-X  0.127
2021 Kishimoto T, Hagi K, Kurokawa S, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. The Lancet. Psychiatry. 8: 387-404. PMID 33862018 DOI: 10.1016/S2215-0366(21)00039-0  0.127
1991 Kane JM, Selzer J. Considerations on 'organic' exclusion criteria for schizophrenia Schizophrenia Bulletin. 17: 69-73. PMID 2047790 DOI: 10.1093/SCHBUL/17.1.69  0.126
2009 Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. Jama. 302: 1765-73. PMID 19861668 DOI: 10.1001/jama.2009.1549  0.126
2008 Kane JM. New-Onset Schizophrenia: Pharmacologic Treatment Focus. 6: 167-171. DOI: 10.1176/FOC.6.2.FOC167  0.126
2011 Gallego JA, Robinson DG, Sevy SM, Napolitano B, McCormack J, Lesser ML, Kane JM. Time to treatment response in first-episode schizophrenia: should acute treatment trials last several months? The Journal of Clinical Psychiatry. 72: 1691-6. PMID 21939612 DOI: 10.4088/JCP.10m06349  0.126
2003 Schooler N, Marder S, Kane J, Wirshing W, Chengappa K, Petrides G, Wirshing D, McMeniman M, Parepally H, Umbricht D, Baker R. Clozapine and risperidone in moderately refractory schizophrenia: A six month double-blind comparison Schizophrenia Research. 60: 302. DOI: 10.1016/S0920-9964(03)80222-0  0.126
1993 Kane JM. Future Directions in Schizophrenia Research Psychiatric Annals. 23: 222-224. DOI: 10.3928/0048-5713-19930401-12  0.126
1999 Kane JM. Pharmacologic treatment of schizophrenia. Biological Psychiatry. 46: 1396-408. PMID 10578454 DOI: 10.1016/S0006-3223(99)00059-1  0.126
1998 Kane JM, Hargreaves WA, Hester TW, Hogan MF, Flynn LM. Commentaries on the Schizophrenia Patient Outcomes Research Team (PORT) Studies Schizophrenia Bulletin. 24: 20-32. DOI: 10.1093/OXFORDJOURNALS.SCHBUL.A033310  0.126
2011 Kane JM. Addressing side effects from antipsychotic treatment in schizophrenia. The Journal of Clinical Psychiatry. 72: e07. PMID 21382302 DOI: 10.4088/JCP.9101tx3c  0.126
2012 Alphs L, Benedetti F, Fleischhacker WW, Kane JM. Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it? The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 15: 1003-14. PMID 22217384 DOI: 10.1017/S1461145711001738  0.126
1986 Kane JM, Woerner M, Lieberman JA, Kinon BJ. Tardive dyskinesias and drugs Drug Development Research. 9: 41-51. DOI: 10.1002/Ddr.430090106  0.126
2016 Ben-Zeev D, Scherer EA, Gottlieb JD, Rotondi AJ, Brunette MF, Achtyes ED, Mueser KT, Gingerich S, Brenner CJ, Begale M, Mohr DC, Schooler N, Marcy P, Robinson DG, Kane JM. mHealth for Schizophrenia: Patient Engagement With a Mobile Phone Intervention Following Hospital Discharge. Jmir Mental Health. 3: e34. PMID 27465803 DOI: 10.2196/Mental.6348  0.126
2021 Rubio JM, Malhotra AK, Kane JM. Towards a framework to develop neuroimaging biomarkers of relapse in schizophrenia. Behavioural Brain Research. 402: 113099. PMID 33417996 DOI: 10.1016/j.bbr.2020.113099  0.126
2013 Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry : Official Journal of the World Psychiatric Association (Wpa). 12: 216-26. PMID 24096780 DOI: 10.1002/wps.20060  0.126
2007 Szeszko PR, Robinson DG, Sevy S, Kumra S, Rupp CI, Betensky JD, Lencz T, Ashtari M, Kane JM, Malhotra AK, Gunduz-Bruce H, Napolitano B, Bilder RM. Anterior cingulate grey-matter deficits and cannabis use in first-episode schizophrenia. The British Journal of Psychiatry : the Journal of Mental Science. 190: 230-6. PMID 17329743 DOI: 10.1192/bjp.bp.106.024521  0.125
2013 Loebel A, Cucchiaro J, Xu J, Sarma K, Pikalov A, Kane JM. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study. Schizophrenia Research. 147: 95-102. PMID 23583011 DOI: 10.1016/j.schres.2013.03.013  0.125
2003 Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. The American Journal of Psychiatry. 160: 1209-22. PMID 12832232 DOI: 10.1176/APPI.AJP.160.7.1209  0.125
2000 Bilder RM, Goldman RS, Robinson D, Reiter G, Bell L, Bates JA, Pappadopulos E, Willson DF, Alvir JM, Woerner MG, Geisler S, Kane JM, Lieberman JA. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. The American Journal of Psychiatry. 157: 549-59. PMID 10739413 DOI: 10.1176/Appi.Ajp.157.4.549  0.125
2017 Kane J. 119. The Pharmacologic Treatment of Schizophrenia: How Far Have We Come Schizophrenia Bulletin. 43: S67-S67. DOI: 10.1093/schbul/sbx021.177  0.125
2013 Kishimoto T, Agarwal V, Kishi T, Leucht S, Kane JM, Correll CU. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Molecular Psychiatry. 18: 53-66. PMID 22124274 DOI: 10.1038/mp.2011.143  0.125
2005 Szeszko PR, Ardekani BA, Ashtari M, Kumra S, Robinson DG, Sevy S, Gunduz-Bruce H, Malhotra AK, Kane JM, Bilder RM, Lim KO. White matter abnormalities in first-episode schizophrenia or schizoaffective disorder: a diffusion tensor imaging study. The American Journal of Psychiatry. 162: 602-5. PMID 15741480 DOI: 10.1176/appi.ajp.162.3.602  0.125
2001 Kane J, Eerdekens M, Keith S, Lesem M, Karcher K, Lindenmayer J. Long-acting risperidone microspheres for treatment of patients with schizophrenia European Neuropsychopharmacology. 11: S292. DOI: 10.1016/S0924-977X(01)80385-0  0.125
2019 Iwata N, Ishigooka J, Kim WH, Yoon BH, Lin SK, Sulaiman AH, Cosca R, Wang L, Suchkov Y, Agarkov A, Watabe K, Matsui T, Sato T, Inoue Y, Higuchi T, ... ... Kane JM, et al. Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: A 6-week randomized, double-blind, placebo-controlled, multicenter study. Schizophrenia Research. PMID 31471246 DOI: 10.1016/j.schres.2019.07.055  0.125
2010 Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Zhou W, Kapur S, Kane JM. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 35: 581-90. PMID 19890258 DOI: 10.1038/npp.2009.164  0.124
2020 He-Yueya J, Buck B, Campbell A, Choudhury T, Kane JM, Ben-Zeev D, Althoff T. Assessing the relationship between routine and schizophrenia symptoms with passively sensed measures of behavioral stability. Npj Schizophrenia. 6: 35. PMID 33230099 DOI: 10.1038/s41537-020-00123-2  0.124
2008 Leucht C, Kitzmantel M, Chua L, Kane J, Leucht S. Haloperidol versus chlorpromazine for treatment of schizophrenia. Schizophrenia Bulletin. 34: 813-5. PMID 18658127 DOI: 10.1093/schbul/sbn087  0.124
2012 Szeszko PR, Narr KL, Phillips OR, McCormack J, Sevy S, Gunduz-Bruce H, Kane JM, Bilder RM, Robinson DG. Magnetic resonance imaging predictors of treatment response in first-episode schizophrenia. Schizophrenia Bulletin. 38: 569-78. PMID 21084552 DOI: 10.1093/Schbul/Sbq126  0.124
2005 Lasser RA, Bossie CA, Gharabawi GM, Kane JM. Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection. Schizophrenia Research. 77: 215-27. PMID 15908183 DOI: 10.1016/j.schres.2005.03.006  0.124
2004 Bellack AS, Schooler NR, Marder SR, Kane JM, Brown CH, Yang Y. Do clozapine and risperidone affect social competence and problem solving? The American Journal of Psychiatry. 161: 364-7. PMID 14754789 DOI: 10.1176/Appi.Ajp.161.2.364  0.124
2006 Kane JM, Khanna S, Rajadhyaksha S, Giller E. Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia. International Clinical Psychopharmacology. 21: 21-8. PMID 16317313 DOI: 10.1097/01.YIC.0000182114.65134.81  0.124
2013 Guha S, Rees E, Darvasi A, Ivanov D, Ikeda M, Bergen SE, Magnusson PK, Cormican P, Morris D, Gill M, Cichon S, Rosenfeld JA, Lee A, Gregersen PK, Kane JM, et al. Implication of a rare deletion at distal 16p11.2 in schizophrenia. Jama Psychiatry. 70: 253-60. PMID 23325106 DOI: 10.1001/2013.Jamapsychiatry.71  0.124
2014 Ikuta T, Robinson DG, Gallego JA, Peters BD, Gruner P, Kane J, John M, Sevy S, Malhotra AK, Szeszko PR. Subcortical modulation of attentional control by second-generation antipsychotics in first-episode psychosis. Psychiatry Research. 221: 127-34. PMID 24120303 DOI: 10.1016/J.Pscychresns.2013.09.010  0.123
1980 Quitkin FM, Rifkin A, Tsuang MT, Kane JM, Klein DF. Can schizophrenia with premorbid asociality be genetically distinguished from the other forms of schizophrenia? Psychiatry Research. 2: 99-105. PMID 6932057 DOI: 10.1016/0165-1781(80)90010-4  0.123
2017 Kane J, Birnbaum M. 178.2 Developing Strategies to Reduce DUP in the Age of Social Media and the Internet Schizophrenia Bulletin. 43: S94-S95. DOI: 10.1093/schbul/sbx021.254  0.123
2018 Zhang JP, Robinson D, Yu J, Gallego J, Fleischhacker WW, Kahn RS, Crespo-Facorro B, Vazquez-Bourgon J, Kane JM, Malhotra AK, Lencz T. Schizophrenia Polygenic Risk Score as a Predictor of Antipsychotic Efficacy in First-Episode Psychosis. The American Journal of Psychiatry. appiajp201817121363. PMID 30392411 DOI: 10.1176/Appi.Ajp.2018.17121363  0.123
2000 Kane J. The treatment of schizophrenia in the next decades European Neuropsychopharmacology. 10: 107. DOI: 10.1016/S0924-977X(00)80001-2  0.123
2017 Birnbaum ML, Garrett C, Baumel A, Scovel M, Rizvi AF, Muscat W, Kane JM. Using Digital Media Advertising in Early Psychosis Intervention. Psychiatric Services (Washington, D.C.). appips201600571. PMID 28712355 DOI: 10.1176/appi.ps.201600571  0.123
2007 Kane JM, Meltzer HY, Carson WH, McQuade RD, Marcus RN, Sanchez R. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. The Journal of Clinical Psychiatry. 68: 213-23. PMID 17335319 DOI: 10.4088/Jcp.V68N0206  0.123
2020 Rubio JM, Schoretsanitis G, John M, Tiihonen J, Taipale H, Guinart D, Malhotra AK, Correll CU, Kane JM. Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis. The Lancet. Psychiatry. 7: 749-761. PMID 32828165 DOI: 10.1016/S2215-0366(20)30264-9  0.123
2001 Kane JM. Extrapyramidal side effects are unacceptable. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. S397-403. PMID 11587887 DOI: 10.1016/S0924-977X(01)00109-2  0.122
2008 Correll CU, Frederickson AM, Figen V, Ginn-Scott EJ, Pantaleon Moya RA, Kane JM, Manu P. The QTc interval and its dispersion in patients receiving two atypical antipsychotics. European Archives of Psychiatry and Clinical Neuroscience. 259: 23-7. PMID 18574608 DOI: 10.1007/s00406-008-0829-4  0.122
2002 Umbricht DS, Wirshing WC, Wirshing DA, McMeniman M, Schooler NR, Marder SR, Kane JM. Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. The Journal of Clinical Psychiatry. 63: 420-4. PMID 12019667 DOI: 10.4088/JCP.V63N0508  0.122
1995 Kane JM, Barnes TR. Schizophrenia research Current Opinion in Psychiatry. 8: 19-20. DOI: 10.1097/00001504-199501000-00005  0.122
2017 Sint K, Rosenheck R, Robinson DG, Schooler NR, Marcy P, Kane JM, Mueser KT, Lin H. Accounting for group differences in study retention in a randomized trial of specialized treatment for first episode psychosis. Schizophrenia Research. PMID 28844431 DOI: 10.1016/J.Schres.2017.08.029  0.122
2013 Fleischhacker WW, Perry P, Sanchez R, Jin N, Peters-Strickland T, Johnson B, Baker R, Eramo A, McQuade RD, Carson WH, Kane JM. Functional Outcomes with Aripiprazole Once-Monthly in Two Double-Blind, Placebo- and Active-Controlled Studies (Aspire US 246 and Aspire EU 247) for the Treatment of Schizophrenia Value in Health. 16. DOI: 10.1016/J.Jval.2013.08.1419  0.122
2007 Riesgo Y, Talbott S, Eudicone J, Owen R, Tran Q, Pikalov A, Kane J. Assessment of akathisia in acute schizophrenia and schizoaffective disorder patients: A pooled analysis of 5 placebo-controlled, double-blind studies with aripiprazole European Psychiatry. 22: S134-S135. DOI: 10.1016/j.eurpsy.2007.01.431  0.122
2020 Durgam S, Satlin A, Davis RE, Vanover KE, Mates S, Kane JM. T205. LUMATEPERONE IN THE TREATMENT OF SCHIZOPHRENIA: EVALUATION OF EXTRAPYRAMIDAL AND MOTOR SYMPTOMS IN 4 LATE-PHASE CLINICAL TRIALS Schizophrenia Bulletin. 46: S310-S310. DOI: 10.1093/schbul/sbaa029.765  0.121
2012 Kishi T, Fukuo Y, Okochi T, Kawashima K, Moriwaki M, Furukawa O, Fujita K, Musso GM, Correll CU, Kane JM, Iwata N. The relationship between acoustic startle response measures and cognitive functions in Japanese patients with schizophrenia. Neuromolecular Medicine. 14: 131-8. PMID 22454047 DOI: 10.1007/s12017-012-8177-y  0.121
2013 Fleischhacker WW, Sanchez R, Jin N, Peters-Strickland T, Johnson BR, Eramo A, Loze JY, McQuade RD, Carson WH, Kane J. P.3.d.028 Personal and social performance in schizophrenia: double-blind, non-inferiority study of once-monthly vs oral aripiprazole European Neuropsychopharmacology. 23. DOI: 10.1016/S0924-977X(13)70751-X  0.121
2015 Gallego JA, Rachamallu V, Yuen EY, Fink S, Duque LM, Kane JM. Predictors of suicide attempts in 3.322 patients with affective disorders and schizophrenia spectrum disorders. Psychiatry Research. 228: 791-6. PMID 26077849 DOI: 10.1016/J.Psychres.2015.05.024  0.121
2019 Emsley R, Asmal L, Rubio JM, Correll CU, Kane JM. Predictors of psychosis breakthrough during 24 months of long-acting antipsychotic maintenance treatment in first episode schizophrenia. Schizophrenia Research. PMID 31767510 DOI: 10.1016/j.schres.2019.11.025  0.121
1997 Robison DG, Lieberman JA, Sheitman B, Alvir JMJ, Kane JM. Pilot study of atypical antipsychotic agents in first episode schizophrenia Schizophrenia Research. 24: 196. DOI: 10.1016/S0920-9964(97)82561-3  0.121
2011 Kane JM. Recent advances in treatments for schizophrenia. The Journal of Clinical Psychiatry. 72: 3. PMID 22217435 DOI: 10.4088/JCP.10075su1.00  0.121
2012 Kane JM, Fleischhacker W, Kolitsopoulos F, Karayal ON, Geier J, Siu C, Reynolds R, Faich G, Strom BL. Regional disease characteristics and comorbidities of patients with schizophrenia in the Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC): Findings from an international large simple trial Open Journal of Psychiatry. 2: 423-432. DOI: 10.4236/Ojpsych.2012.224059  0.121
2017 Galling B, Roldán A, Hagi K, Rietschel L, Walyzada F, Zheng W, Cao XL, Xiang YT, Zink M, Kane JM, Nielsen J, Leucht S, Correll CU. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry : Official Journal of the World Psychiatric Association (Wpa). 16: 77-89. PMID 28127934 DOI: 10.1002/Wps.20387  0.121
2009 Kane JM, Osuntokun O, Kryzhanovskaya LA, Xu W, Stauffer VL, Watson SB, Breier A. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. The Journal of Clinical Psychiatry. 70: 572-81. PMID 19323965 DOI: 10.4088/JCP.08m04421  0.121
2007 Lasser RA, Bossie CA, Zhu Y, Locklear JC, Kane JM. Long-acting risperidone in young adults with early schizophrenia or schizoaffective illness. Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists. 19: 65-71. PMID 17612845 DOI: 10.1080/10401230701332931  0.12
2003 Cornell C, Kane J, O'Shea D, Razi K, Malhotra A. Antipsychotic polypharmacy in the treatment of schizophrenia Schizophrenia Research. 60: 37. DOI: 10.1016/S0920-9964(03)80107-X  0.12
2017 Kane J, Josiassen R, Burke J, Jimenez R, Siegert S, Liang G. SA17. Response to Treatment With Valbenazine (NBI-98854) in Subjects With Tardive Dyskinesia Schizophrenia Bulletin. 43: S119-S119. DOI: 10.1093/Schbul/Sbx023.016  0.12
2019 Birnbaum ML, Ernala SK, Rizvi AF, Arenare E, R Van Meter A, De Choudhury M, Kane JM. Detecting relapse in youth with psychotic disorders utilizing patient-generated and patient-contributed digital data from Facebook. Npj Schizophrenia. 5: 17. PMID 31591400 DOI: 10.1038/s41537-019-0085-9  0.12
2014 Eramo A, Fleischhacker WW, Sanchez R, Tsai L, Peters-Strickland TS, Baker RA, Kostic D, Kane JM. Poster #S233 ALL-CAUSE DISCONTINUATION AND SAFETY OF ARIPIPRAZOLE ONCE-MONTHLY FOR THE TREATMENT OF SCHIZOPHRENIA: A POOLED ANALYSIS OF TWO DOUBLE-BLIND, RANDOMIZED, CONTROLLED TRIALS Schizophrenia Research. 153. DOI: 10.1016/S0920-9964(14)70512-2  0.12
2008 Assunção-Talbott S, Crandall D, Eudicone JM, Pikalov A, McQuade RD, Kane JM. COMPARISON OF REMISSION RATES AND TOLERABILITY IN PATIENTS WITH EARLY-EPISODE SCHIZOPHRENIA RECEIVING ARIPIPRAZOLE OR HALOPERIDOL Schizophrenia Research. 102: 261. DOI: 10.1016/S0920-9964(08)70785-0  0.12
2006 Kane J. C.01.03 Sustained remission as new standard for outcome in schizophrenia, changing longterm prognosis earlier in its course European Neuropsychopharmacology. 16: S571-S572. DOI: 10.1016/S0924-977X(06)70814-8  0.12
2020 Correll CU, Davis RE, Weingart M, Saillard J, O'Gorman C, Kane JM, Lieberman JA, Tamminga CA, Mates S, Vanover KE. Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial. Jama Psychiatry. PMID 31913424 DOI: 10.1001/Jamapsychiatry.2019.4379  0.12
2016 Buckley PF, Schooler NR, Goff DC, Kopelowicz A, Lauriello J, Manschreck TC, Mendelowitz A, Miller DD, Wilson DR, Ames D, Bustillo JR, Kane JM, Looney SW. Comparison of Injectable and Oral Antipsychotics in Relapse Rates in a Pragmatic 30-Month Schizophrenia Relapse Prevention Study. Psychiatric Services (Washington, D.C.). appips201500466. PMID 27476806 DOI: 10.1176/Appi.Ps.201500466  0.12
2009 Leucht S, Davis JM, Engel RR, Kissling W, Kane JM. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatrica Scandinavica. Supplementum. 7-14. PMID 19132961 DOI: 10.1111/j.1600-0447.2008.01308.x  0.12
1998 Kane JM. Sertindole International Clinical Psychopharmacology. 13: S59-S64. DOI: 10.1097/00004850-199803003-00010  0.12
2017 Kishimoto T, Sanghani S, Russ MJ, Marsh AN, Morris J, Basu S, John M, Kane JM. Indications for and use of long-acting injectable antipsychotics: consideration from an inpatient setting. International Clinical Psychopharmacology. PMID 28181959 DOI: 10.1097/YIC.0000000000000165  0.12
2021 Kane JM. Lessening the Side Effect Burden to Improve Adherence Among Individuals With Schizophrenia. The Journal of Clinical Psychiatry. 82. PMID 34033269 DOI: 10.4088/JCP.IC20018BR1C  0.12
2007 Correll CU, Penzner JB, Frederickson AM, Richter JJ, Auther AM, Smith CW, Kane JM, Cornblatt BA. Differentiation in the preonset phases of schizophrenia and mood disorders: evidence in support of a bipolar mania prodrome. Schizophrenia Bulletin. 33: 703-14. PMID 17478437 DOI: 10.1093/schbul/sbm028  0.12
1995 Kane JM, McGlashan TH. Treatment of schizophrenia. Lancet (London, England). 346: 820-5. PMID 7545770 DOI: 10.1016/S0140-6736(95)91630-X  0.119
1999 Kane JM. Schizophrenia: how far have we come? Current Opinion in Psychiatry. 12: 17-18. DOI: 10.1097/00001504-199901000-00012  0.119
2008 Detke H, McDonnell D, Kane J, Naber D, Sethuraman G, Lin D. OLANZAPINE LONG-ACTING INJECTION FOR THE MAINTENANCE TREATMENT OF SCHIZOPHRENIA: A 24-WEEK, RANDOMIZED, DOUBLE-BLIND TRIAL Schizophrenia Research. 102: 262-263. DOI: 10.1016/S0920-9964(08)70791-6  0.119
1989 Lieberman J, Johns C, Cooper T, Pollack S, Kane J. Clozapine pharmacology and tardive dyskinesia Psychopharmacology. 99. PMID 2479047 DOI: 10.1007/Bf00442560  0.119
2016 Kane JM, Skuban A, Hobart M, Ouyang J, Weiller E, Weiss C, U Correll C. Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia. Schizophrenia Research. PMID 27188270 DOI: 10.1016/j.schres.2016.04.013  0.119
2008 Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophrenia Bulletin. 35: 443-57. PMID 18417466 DOI: 10.1093/schbul/sbn018  0.119
1996 Kane J. Lack of treatment and development of treatment refractoriness in schizophrenia European Neuropsychopharmacology. 6: 221. DOI: 10.1016/0924-977X(96)88344-1  0.119
2005 Breier A, Berg PH, Thakore JH, Naber D, Gattaz WF, Cavazzoni P, Walker DJ, Roychowdhury SM, Kane JM. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. The American Journal of Psychiatry. 162: 1879-87. PMID 16199834 DOI: 10.1176/Appi.Ajp.162.10.1879  0.119
2014 Kishimoto T, Robenzadeh A, Leucht C, Leucht S, Watanabe K, Mimura M, Borenstein M, Kane JM, Correll CU. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophrenia Bulletin. 40: 192-213. PMID 23256986 DOI: 10.1093/schbul/sbs150  0.119
2011 Kane JM. Improving treatment adherence in patients with schizophrenia. The Journal of Clinical Psychiatry. 72: e28. PMID 21951990 DOI: 10.4088/JCP.9101tx2c  0.119
2013 Zhang JP, Gallego JA, Robinson DG, Malhotra AK, Kane JM, Correll CU. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 16: 1205-18. PMID 23199972 DOI: 10.1017/S1461145712001277  0.119
2020 Rubio J, Fales C, Barber A, Lencz T, Malhotra A, Kane J. T23. ANTIPSYCHOTIC EXPOSURE AND STRIATAL FUNCTIONAL CONNECTIVITY IN PSYCHOSIS RELAPSE: A HYPOTHESIS GENERATING STUDY Schizophrenia Bulletin. 46: S240-S240. DOI: 10.1093/schbul/sbaa029.583  0.118
2011 Ruberg SJ, Chen L, Stauffer V, Ascher-Svanum H, Kollack-Walker S, Conley RR, Kane J, Kinon BJ. Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia. Bmc Psychiatry. 11: 23. PMID 21306626 DOI: 10.1186/1471-244X-11-23  0.118
2011 Sevy S, Robinson DG, Sunday S, Napolitano B, Miller R, McCormack J, Kane J. Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes. Psychiatry Research. 188: 310-4. PMID 21636134 DOI: 10.1016/j.psychres.2011.05.001  0.118
2004 Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, Kane JM, Lieberman JA, Schooler NR, Covell N, Stroup S, Weissman EM, Wirshing DA, Hall CS, Pogach L, et al. Physical health monitoring of patients with schizophrenia. The American Journal of Psychiatry. 161: 1334-49. PMID 15285957 DOI: 10.1176/Appi.Ajp.161.8.1334  0.118
2006 Burdick KE, Lencz T, Funke B, Finn CT, Szeszko PR, Kane JM, Kucherlapati R, Malhotra AK. Genetic variation in DTNBP1 influences general cognitive ability. Human Molecular Genetics. 15: 1563-8. PMID 16415041 DOI: 10.1093/Hmg/Ddi481  0.118
2010 Kane JM, Cohen M, Zhao J, Alphs L, Panagides J. Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. Journal of Clinical Psychopharmacology. 30: 106-15. PMID 20520283 DOI: 10.1097/JCP.0b013e3181d35d6b  0.118
2008 Kane JM, Assunção-Talbott S, Eudicone JM, Pikalov A, Whitehead R, Crandall DT. The efficacy of aripiprazole in the treatment of multiple symptom domains in patients with acute schizophrenia: a pooled analysis of data from the pivotal trials. Schizophrenia Research. 105: 208-15. PMID 18790605 DOI: 10.1016/j.schres.2008.06.018  0.118
2014 Fleischhacker WW, Sanchez R, Perry PP, Jin N, Peters-Strickland T, Johnson BR, Baker RA, Eramo A, McQuade RD, Carson WH, Walling D, Kane JM. Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. The British Journal of Psychiatry : the Journal of Mental Science. 205: 135-44. PMID 24925984 DOI: 10.1192/Bjp.Bp.113.134213  0.118
2015 Osipov M, Behzadi Y, Kane JM, Petrides G, Clifford GD. Objective identification and analysis of physiological and behavioral signs of schizophrenia. Journal of Mental Health (Abingdon, England). 24: 276-82. PMID 26193048 DOI: 10.3109/09638237.2015.1019048  0.118
2012 Loze J, Carson W, Perry P, Sanchez R, Jin N, Forbes R, McQuade R, Kane J, Fleischhacker W. P.3.c.019 Psychosocial and overall effectiveness of aripiprazole intramuscular depot vs. placebo for maintenance treatment in schizophrenia European Neuropsychopharmacology. 22: S328. DOI: 10.1016/S0924-977X(12)70503-5  0.118
2015 Stentebjerg-Olesen M, Ganocy SJ, Findling RL, Chang K, DelBello MP, Kane JM, Tohen M, Jeppesen P, Correll CU. Early response or nonresponse at week 2 and week 3 predict ultimate response or nonresponse in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial. European Child & Adolescent Psychiatry. PMID 26032132 DOI: 10.1007/s00787-015-0725-1  0.118
2008 Vinall M, Crandall DT, Glick ID, Kane JM, Janicak PG, Meyer JM. Aripiprazole for the Treatment of Schizophrenia--Selected Posters Md Conference Express. 8: 15-16. DOI: 10.1177/155989770800800312  0.117
1994 Chakos M, Alvir J, Bilder R, Woerner M, Kane J, Lieberman J. Predictors of Tardive Dyskinesia in First Episode Schizophrenia Neuropsychopharmacology. 11: 267-267. DOI: 10.1038/Sj.Npp.1380141  0.117
2021 Achtyes ED, Kempema K, Luo Z, Thakkar KN, Adams C, D'Mello D, Stilwell K, Tran D, Marcy P, Mueser K, Schooler NR, Robinson DG, Kane JM. Implementation of NAVIGATE Coordinated Specialty Care for First Episode Psychosis: the Michigan Experience. Cns Spectrums. 26: 177-178. PMID 34127084 DOI: 10.1017/S1092852920002928  0.117
2008 Szeszko PR, Hodgkinson CA, Robinson DG, Derosse P, Bilder RM, Lencz T, Burdick KE, Napolitano B, Betensky JD, Kane JM, Goldman D, Malhotra AK. DISC1 is associated with prefrontal cortical gray matter and positive symptoms in schizophrenia. Biological Psychology. 79: 103-10. PMID 18078707 DOI: 10.1016/J.Biopsycho.2007.10.011  0.117
2020 Adler DA, Ben-Zeev D, Tseng VW, Kane JM, Brian R, Campbell AT, Hauser M, Scherer EA, Choudhury T. Predicting Early Warning Signs of Psychotic Relapse From Passive Sensing Data: An Approach Using Encoder-Decoder Neural Networks. Jmir Mhealth and Uhealth. 8: e19962. PMID 32865506 DOI: 10.2196/19962  0.117
2014 Kane JM. Attitudinal barriers to prescribing LAI antipsychotics in the outpatient setting: communicating with patients, families, and caregivers. The Journal of Clinical Psychiatry. 75: e33. PMID 25551245 DOI: 10.4088/JCP.13024tx2c  0.117
2018 Sajatovic M, Ross R, Legacy SN, Byerly M, Kane JM, DiBiasi F, Fitzgerald H, Correll CU. Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder - expert consensus survey part 2. Neuropsychiatric Disease and Treatment. 14: 1475-1492. PMID 29922063 DOI: 10.2147/NDT.S167485  0.117
1997 Kane JM. The facilitation of early detection and treatment of schizophrenia Current Opinion in Psychiatry. 10: 3. DOI: 10.1097/00001504-199701000-00002  0.117
2007 Gunduz-Bruce H, Szeszko PR, Gueorguieva R, Ashtari M, Robinson DG, Kane JM, Bilder RM. Cortisol levels in relation to hippocampal sub-regions in subjects with first episode schizophrenia. Schizophrenia Research. 94: 281-7. PMID 17490857 DOI: 10.1016/j.schres.2007.03.025  0.117
2012 Kane JM. Addressing nonresponse in schizophrenia. The Journal of Clinical Psychiatry. 73: e07. PMID 22401484 DOI: 10.4088/JCP.11076tx2c  0.116
2021 Kishimoto T, Hagi K, Kurokawa S, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics for schizophrenia - Authors' reply. The Lancet. Psychiatry. 8: 567. PMID 34147177 DOI: 10.1016/S2215-0366(21)00203-0  0.116
2008 Leucht S, Heres S, Hamann J, Kane JM. Methodological issues in current antipsychotic drug trials. Schizophrenia Bulletin. 34: 275-85. PMID 18234700 DOI: 10.1093/schbul/sbm159  0.116
2007 Kane JM. Treatment adherence and long-term outcomes. Cns Spectrums. 12: 21-6. PMID 17934386 DOI: 10.1017/S1092852900026304  0.116
2005 Gunduz-Bruce H, McMeniman M, Robinson DG, Woerner MG, Kane JM, Schooler NR, Lieberman JA. Duration of untreated psychosis and time to treatment response for delusions and hallucinations. The American Journal of Psychiatry. 162: 1966-9. PMID 16199847 DOI: 10.1176/Appi.Ajp.162.10.1966  0.116
2016 Yu X, Correll CU, Xiang YT, Xu Y, Huang J, Yang F, Wang G, Si T, Kane JM, Masand P. Efficacy of Atypical Antipsychotics in the Management of Acute Agitation and Aggression in Hospitalized Patients with Schizophrenia or Bipolar Disorder: Results from a Systematic Review. Shanghai Archives of Psychiatry. 28: 241-252. PMID 28638198 DOI: 10.11919/j.issn.1002-0829.216072  0.116
2013 Naber D, Kollack-Walker S, Chen J, Stauffer VL, Kinon BJ, Case M, Ascher-Svanum H, Kapur S, Kane JM. Predicting a 'combined treatment outcome' in chronic schizophrenia: the role of demographics, symptomatology, functioning and subjective well-being. Pharmacopsychiatry. 46: 114-9. PMID 23293013 DOI: 10.1055/s-0032-1331703  0.116
1989 Lieberman J, Johns C, Cooper T, Kane J. Biochemical effects of clozapine in schizophrenia Schizophrenia Research. 2: 164. DOI: 10.1016/0920-9964(89)90200-4  0.116
2016 Brunette MF, Rotondi AJ, Ben-Zeev D, Gottlieb JD, Mueser KT, Robinson DG, Achtyes ED, Gingerich S, Marcy P, Schooler NR, Meyer-Kalos P, Kane JM. Coordinated Technology-Delivered Treatment to Prevent Rehospitalization in Schizophrenia: A Novel Model of Care. Psychiatric Services (Washington, D.C.). appips201500257. PMID 26725297 DOI: 10.1176/appi.ps.201500257  0.115
2008 Kumra S, Kranzler H, Gerbino-Rosen G, Kester HM, DeThomas C, Cullen K, Regan J, Kane JM. Clozapine versus "high-dose" olanzapine in refractory early-onset schizophrenia: an open-label extension study. Journal of Child and Adolescent Psychopharmacology. 18: 307-16. PMID 18759640 DOI: 10.1089/cap.2007.0089  0.115
2021 Buck B, Hallgren KA, Campbell AT, Choudhury T, Kane JM, Ben-Zeev D. mHealth-Assisted Detection of Precursors to Relapse in Schizophrenia. Frontiers in Psychiatry. 12: 642200. PMID 34135781 DOI: 10.3389/fpsyt.2021.642200  0.115
2017 Fusar-Poli P, McGorry PD, Kane JM. Improving outcomes of first-episode psychosis: an overview. World Psychiatry : Official Journal of the World Psychiatric Association (Wpa). 16: 251-265. PMID 28941089 DOI: 10.1002/Wps.20446  0.115
2005 Kane JM. Reply to Orally Distegrating Antipsychotics May Promote Compliance and Adherence in Patients With Schizophrenia The Journal of Clinical Psychiatry. 66: 1494. DOI: 10.4088/JCP.V66N1121F  0.115
2021 de Filippis R, Gaetano R, Schoretsanitis G, Verde G, Oliveti CA, Kane JM, Segura-Garcia C, De Fazio P. Clozapine Management in Schizophrenia Inpatients: A 5-Year Prospective Observational Study of Its Safety and Tolerability Profile. Neuropsychiatric Disease and Treatment. 17: 2141-2150. PMID 34234440 DOI: 10.2147/NDT.S312095  0.115
2018 Achtyes ED, Ben-Zeev D, Luo Z, Mayle H, Burke B, Rotondi AJ, Gottlieb JD, Brunette MF, Mueser KT, Gingerich S, Meyer-Kalos PS, Marcy P, Schooler NR, Robinson DG, Kane JM. Off-hours use of a smartphone intervention to extend support for individuals with schizophrenia spectrum disorders recently discharged from a psychiatric hospital. Schizophrenia Research. PMID 30551981 DOI: 10.1016/j.schres.2018.11.026  0.115
2009 Goldberg TE, Burdick KE, McCormack J, Napolitano B, Patel RC, Sevy SM, Goldman R, Lencz T, Malhotra AK, Kane JM, Robinson DG. Lack of an inverse relationship between duration of untreated psychosis and cognitive function in first episode schizophrenia. Schizophrenia Research. 107: 262-6. PMID 19042105 DOI: 10.1016/J.Schres.2008.11.003  0.115
2014 Correll CU, Kane JM. Schizophrenia: mechanism of action of current and novel treatments. The Journal of Clinical Psychiatry. 75: 347-8. PMID 24813403 DOI: 10.4088/JCP.13078co8c  0.115
2017 Baumel A, Pawar A, Mathur N, Kane JM, Correll CU. Technology-Assisted Parent Training Programs for Children and Adolescents With Disruptive Behaviors: A Systematic Review. The Journal of Clinical Psychiatry. PMID 28493653 DOI: 10.4088/JCP.16r11063  0.115
2015 Ben-Zeev D, Wang R, Abdullah S, Brian R, Scherer EA, Mistler LA, Hauser M, Kane JM, Campbell A, Choudhury T. Mobile Behavioral Sensing for Outpatients and Inpatients With Schizophrenia. Psychiatric Services (Washington, D.C.). appips201500130. PMID 26695497 DOI: 10.1176/appi.ps.201500130  0.115
1997 Lieberman J, Chatterjee A, Chakos M, Koreen A, Geisler S, Sheitman B, Woemer M, Kane JM, Alvir J. Extrapyramidal signs in dyskinesia in first episode schizophrenia Biological Psychiatry. 42. DOI: 10.1016/S0006-3223(97)87447-1  0.114
1994 Aronowitz J, Wu H, Pollack S, Bilder R, Kane J, Safferman A, Lieberman J. Clozapine Response In Chronic Schizophrenia And Brain Morphology On MRI: A Preliminary Report Neuropsychopharmacology. 11: 265-265. DOI: 10.1038/Sj.Npp.1380132  0.114
2016 Correll CU, Maayan L, Kane J, Hert MD, Cohen D. Efficacy for Psychopathology and Body Weight and Safety of Topiramate-Antipsychotic Cotreatment in Patients With Schizophrenia Spectrum Disorders: Results From a Meta-Analysis of Randomized Controlled Trials. The Journal of Clinical Psychiatry. 77: e746-56. PMID 27337425 DOI: 10.4088/Jcp.15R10373  0.114
2017 Correll CU, Skuban A, Hobart M, Ouyang J, Weiller E, Weiss C, Kane JM. Corrigendum to "Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studies" [Schizophr. Res. 174 (2016) 82-92]. Schizophrenia Research. PMID 28351543 DOI: 10.1016/j.schres.2017.02.030  0.114
2010 Kane JM. Maintenance strategies in schizophrenia. Cns Spectrums. 15: 12-4. PMID 21141655 DOI: 10.1017/S109285290002770X  0.114
1993 Kane J. Treatment duration of psychiatric disorders: long-term treatment of resistant schizophrenia European Psychiatry. 8: 281-283. DOI: 10.1017/S0924933800000651  0.114
2007 Funke BH, Lencz T, Finn CT, DeRosse P, Poznik GD, Plocik AM, Kane J, Rogus J, Malhotra AK, Kucherlapati R. Analysis of TBX1 variation in patients with psychotic and affective disorders. Molecular Medicine (Cambridge, Mass.). 13: 407-14. PMID 17622328 DOI: 10.2119/2006-00119.FUNKE  0.114
2006 Helldin L, Kane JM, Karilampi U, Norlander T, Archer T. Remission and cognitive ability in a cohort of patients with schizophrenia. Journal of Psychiatric Research. 40: 738-45. PMID 16963087 DOI: 10.1016/J.JPSYCHIRES.2006.07.005  0.114
2014 Li H, Luo J, Wang C, Xie S, Xu X, Wang X, Yu W, Gu N, Kane JM. Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a randomized, double-blind, active parallel-controlled, multicenter clinical trial. Schizophrenia Research. 157: 112-9. PMID 24994555 DOI: 10.1016/j.schres.2014.05.040  0.113
2013 Kane JM. Improving patient outcomes in schizophrenia: achieving remission, preventing relapse, and measuring success. The Journal of Clinical Psychiatry. 74: e18. PMID 24107769 DOI: 10.4088/JCP.12117tx1c  0.113
2006 van Os J, Burns T, Cavallaro R, Leucht S, Peuskens J, Helldin L, Bernardo M, Arango C, Fleischhacker W, Lachaux B, Kane JM. Standardized remission criteria in schizophrenia. Acta Psychiatrica Scandinavica. 113: 91-5. PMID 16423159 DOI: 10.1111/j.1600-0447.2005.00659.x  0.113
1996 Kane J. Placebo response in schizophrenia European Neuropsychopharmacology. 6: 153. DOI: 10.1016/0924-977X(96)88014-X  0.113
2002 Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. The Journal of Clinical Psychiatry. 63: 763-71. PMID 12363115 DOI: 10.4088/JCP.V63N0903  0.113
2015 Loebel A, Silva R, Goldman R, Watabe K, Pikalov A, Cucchiaro J, Kane J. Optimizing Treatment with Lurasidone in Patients with Schizophrenia: Results of a Randomized, Double-blind, Placebo-controlled Trial European Psychiatry. 30: 1722. DOI: 10.1016/S0924-9338(15)32096-4  0.113
2007 Kumra S, Kranzler H, Gerbino-Rosen G, Kester HM, De Thomas C, Kafantaris V, Correll CU, Kane JM. Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biological Psychiatry. 63: 524-9. PMID 17651705 DOI: 10.1016/j.biopsych.2007.04.043  0.113
2012 Nielsen J, Kane JM, Correll CU. Real-world effectiveness of clozapine in patients with bipolar disorder: results from a 2-year mirror-image study. Bipolar Disorders. 14: 863-9. PMID 23107278 DOI: 10.1111/bdi.12018  0.113
2012 Kane J. C.03.03 Efficacy of aripiprazole-IM-depot in the treatment of schizophrenia European Neuropsychopharmacology. 22: S444. DOI: 10.1016/S0924-977X(12)70700-9  0.113
2015 Birnbaum ML, Rizvi AF, Correll CU, Kane JM. Role of social media and the Internet in pathways to care for adolescents and young adults with psychotic disorders and non-psychotic mood disorders. Early Intervention in Psychiatry. PMID 25808317 DOI: 10.1111/eip.12237  0.113
1990 Kane JM. Treatment programme and long-term outcome in chronic schizophrenia. Acta Psychiatrica Scandinavica. Supplementum. 358: 151-7. PMID 1978476 DOI: 10.1111/j.1600-0447.1990.tb05309.x  0.113
2014 Williams JB, Kane JM, Kahn RS. SCHIZOPHRENIA RESEARCH: THE CHALLENGE OF MEASUREMENT VARIABILITY Schizophrenia Research. 153: S86. DOI: 10.1016/S0920-9964(14)70275-0  0.112
2008 Kane JM, Leucht S. Unanswered questions in schizophrenia clinical trials. Schizophrenia Bulletin. 34: 302-9. PMID 18199633 DOI: 10.1093/schbul/sbm143  0.112
2003 Lencz T, Bilder RM, Turkel E, Goldman RS, Robinson D, Kane JM, Lieberman JA. Impairments in perceptual competency and maintenance on a visual delayed match-to-sample test in first-episode schizophrenia. Archives of General Psychiatry. 60: 238-43. PMID 12622656 DOI: 10.1001/Archpsyc.60.3.238  0.112
2013 Kane JM, Sanchez R, Zhao J, Duca AR, Johnson BR, McQuade RD, Eramo A, Baker RA, Peters-Strickland T. Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia. Journal of Medical Economics. 16: 917-25. PMID 23663091 DOI: 10.3111/13696998.2013.804411  0.112
2015 Addington J, Heinssen RK, Robinson DG, Schooler NR, Marcy P, Brunette MF, Correll CU, Estroff S, Mueser KT, Penn D, Robinson JA, Rosenheck RA, Azrin ST, Goldstein AB, Severe J, ... Kane JM, et al. Duration of Untreated Psychosis in Community Treatment Settings in the United States. Psychiatric Services (Washington, D.C.). 66: 753-6. PMID 25588418 DOI: 10.1176/Appi.Ps.201400124  0.112
2004 Correll CU, Malhotra AK, Kaushik S, McMeniman M, Kane JM. Early prediction of antipsychotic response in schizophrenia. The American Journal of Psychiatry. 160: 2063-5. PMID 14594760 DOI: 10.1176/APPI.AJP.160.11.2063  0.112
2019 Kurokawa S, Kishimoto T, Su KP, Chang JP, Chang HC, Yu X, Rodrigues-Silva N, Nielsen J, Unadkat A, Castle D, Haddad PM, Rocha D, Gadelha A, Kaliora S, Petrides G, ... ... Kane JM, et al. Psychiatrists' perceptions of medication adherence among patients with schizophrenia: An international survey. Schizophrenia Research. PMID 31371039 DOI: 10.1016/j.schres.2019.07.028  0.112
2011 O'Gorman C, Kapur S, Kolluri S, Kane J. Early improvement on antipsychotic treatment as a predictor of subsequent response in schizophrenia: analyses from ziprasidone clinical studies. Human Psychopharmacology. 26: 282-90. PMID 21638329 DOI: 10.1002/hup.1200  0.112
2019 Kane J. C.07.04 Is there a sense of urgency to optimise relapse prevention and functioning in patients with schizophrenia? European Neuropsychopharmacology. 29: S594-S595. DOI: 10.1016/j.euroneuro.2019.09.063  0.112
2006 Umbricht DS, Bates JA, Lieberman JA, Kane JM, Javitt DC. Electrophysiological indices of automatic and controlled auditory information processing in first-episode, recent-onset and chronic schizophrenia. Biological Psychiatry. 59: 762-72. PMID 16497277 DOI: 10.1016/J.Biopsych.2005.08.030  0.112
2008 Szeszko PR, Narr CL, Phillips OR, McCormack J, Sevy S, Kane JM, Bilder RM, Robinson D. Greater Cortical Thickness In Patients With First-Episode Schizophrenia Who Are Responsive To Atypical Antipsychotics Schizophrenia Research. 102: 5. DOI: 10.1016/S0920-9964(08)70015-X  0.112
1987 Lieberman JA, Kane JM, Alvir J. Provocative tests with psychostimulant drugs in schizophrenia Psychopharmacology. 91: 415-433. PMID 2884687 DOI: 10.1007/BF00216006  0.111
2008 Malhotra AK, Lencz T, Correll CU, Kane JM. Genomics and the future of pharmacotherapy in psychiatry. International Review of Psychiatry (Abingdon, England). 19: 523-30. PMID 17896232 DOI: 10.1080/09540260701563460  0.111
2019 Saito Y, Sakurai H, Kane JM, Schooler NR, Suzuki T, Mimura M, Uchida H. Predicting relapse with residual symptoms in schizophrenia: A secondary analysis of the PROACTIVE trial. Schizophrenia Research. PMID 31672387 DOI: 10.1016/j.schres.2019.10.037  0.111
2008 Leucht C, Kitzmantel M, Chua L, Kane J, Leucht S. Haloperidol versus chlorpromazine for schizophrenia. The Cochrane Database of Systematic Reviews. CD004278. PMID 18254045 DOI: 10.1002/14651858.CD004278.pub2  0.11
2011 Kane JM, Mackle M, Snow-Adami L, Zhao J, Szegedi A, Panagides J. A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. The Journal of Clinical Psychiatry. 72: 349-55. PMID 21367356 DOI: 10.4088/JCP.10m06306  0.11
2017 Correll CU, Kane JM, Citrome LL. Epidemiology, Prevention, and Assessment of Tardive Dyskinesia and Advances in Treatment. The Journal of Clinical Psychiatry. PMID 29022654 DOI: 10.4088/JCP.tv17016ah4c  0.11
2007 Cornblatt BA, Lencz T, Smith CW, Olsen R, Auther AM, Nakayama E, Lesser ML, Tai JY, Shah MR, Foley CA, Kane JM, Correll CU. Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. The Journal of Clinical Psychiatry. 68: 546-57. PMID 17474810 DOI: 10.4088/JCP.v68n0410  0.11
2008 Kane JM, Perlis RH, Malhotra AK. Clinical insights into pharmacogenetics and schizophrenia, part 2. The Journal of Clinical Psychiatry. 69: 1006-13. PMID 18683996 DOI: 10.4088/JCP.V69N0618  0.11
2017 Correll CU, Rubio JM, Inczedy-Farkas G, Birnbaum ML, Kane JM, Leucht S. Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence. Jama Psychiatry. PMID 28514486 DOI: 10.1001/jamapsychiatry.2017.0624  0.11
2019 Kane JM, Schooler NR, Marcy P, Achtyes ED, Correll CU, Robinson DG. Patients With Early-Phase Schizophrenia Will Accept Treatment With Sustained-Release Medication (Long-Acting Injectable Antipsychotics): Results From the Recruitment Phase of the PRELAPSE Trial. The Journal of Clinical Psychiatry. 80. PMID 31050233 DOI: 10.4088/JCP.18m12546  0.11
2008 Correll C, Rummel-Kluge C, Corves C, Kane J, Leucht S. ANTIPSYCHOTIC COMBINATIONS VERSUS MONOTHERAPY IN SCHIZOPHRENIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS Schizophrenia Research. 102: 35. DOI: 10.1016/S0920-9964(08)70110-5  0.11
2018 Solmi M, Pigato G, Kane JM, Correll CU. Clinical risk factors for the development of tardive dyskinesia. Journal of the Neurological Sciences. PMID 29439776 DOI: 10.1016/j.jns.2018.02.012  0.11
2015 Trampush JW, Lencz T, DeRosse P, John M, Gallego JA, Petrides G, Hassoun Y, Zhang JP, Addington J, Kellner CH, Tohen M, Burdick KE, Goldberg TE, Kane JM, Robinson DG, et al. Relationship of Cognition to Clinical Response in First-Episode Schizophrenia Spectrum Disorders. Schizophrenia Bulletin. PMID 26409223 DOI: 10.1093/Schbul/Sbv120  0.11
2016 Loebel A, Silva R, Goldman R, Watabe K, Cucchiaro J, Citrome L, Kane JM. Lurasidone Dose Escalation in Early Nonresponding Patients With Schizophrenia: A Randomized, Placebo-Controlled Study. The Journal of Clinical Psychiatry. PMID 27454547 DOI: 10.4088/JCP.16m10698  0.11
2007 Strom B, Faich G, Eng S, Reynolds R, Rappard F, Kane J. Cardiac risk factors and schizophrenia: An analysis of 18,094 patients enrolled in an international comparative trial of olanzapine and ziprasidone European Psychiatry. 22: S111. DOI: 10.1016/J.Eurpsy.2007.01.352  0.11
2019 Kane J. C.01.02 Individualisation of treatment in schizophrenia European Neuropsychopharmacology. 29: S616. DOI: 10.1016/j.euroneuro.2018.11.972  0.11
2008 Kinon B, Chen L, Stauffer V, Ascher-Svanum H, Zhou W, Tomori O, Kollack-Walker S, Kane J, Kapur S. P.3.c.060 Differences in early responders/early non-responders to atypical antipsychotics on functional outcomes in schizophrenia European Neuropsychopharmacology. 18: S438-S439. DOI: 10.1016/S0924-977X(08)70644-8  0.11
2017 Kunovac J, Kane J, Durgam S, Chang C, Németh G, Laszlovszky I, Earley W. SU14. Characteristics Associated With Relapse in Patients With Schizophrenia: Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Cariprazine Relapse Prevention Trial Schizophrenia Bulletin. 43: S165-S166. DOI: 10.1093/SCHBUL/SBX024.013  0.11
2008 Zhu B, Ascher-Svanum H, Faries DE, Correll CU, Kane JM. Cost of antipsychotic polypharmacy in the treatment of schizophrenia. Bmc Psychiatry. 8: 19. PMID 18394168 DOI: 10.1186/1471-244X-8-19  0.11
1994 Lieberman JA, Alvir J, Geisler S, Ramos-Lorenzi J, Woerner M, Novacenko H, Cooper T, Kane JM. Methylphenidate response, psychopathology and tardive dyskinesia as predictors of relapse in schizophrenia Neuropsychopharmacology. 11: 107-118. PMID 7840862 DOI: 10.1038/Npp.1994.40  0.11
2017 Robinson DG, Schooler NR, Correll CU, John M, Kurian BT, Marcy P, Miller AL, Pipes R, Trivedi MH, Kane JM. Psychopharmacological Treatment in the RAISE-ETP Study: Outcomes of a Manual and Computer Decision Support System Based Intervention. The American Journal of Psychiatry. appiajp201716080919. PMID 28945118 DOI: 10.1176/appi.ajp.2017.16080919  0.11
2017 Brunette MF, Mueser KT, Babbin S, Meyer-Kalos P, Rosenheck R, Correll CU, Cather C, Robinson DG, Schooler NR, Penn DL, Addington J, Estroff SE, Gottlieb J, Glynn SM, Marcy P, ... ... Kane JM, et al. Demographic and clinical correlates of substance use disorders in first episode psychosis. Schizophrenia Research. PMID 28697856 DOI: 10.1016/J.Schres.2017.06.039  0.109
2011 Kane JM, Potkin SG, Daniel DG, Buckley PF. A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia. The Journal of Clinical Psychiatry. 72: 194-204. PMID 20673553 DOI: 10.4088/JCP.07m03733yel  0.109
2014 Correll CU, Robinson DG, Schooler NR, Brunette MF, Mueser KT, Rosenheck RA, Marcy P, Addington J, Estroff SE, Robinson J, Penn DL, Azrin S, Goldstein A, Severe J, Heinssen R, ... Kane JM, et al. Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study. Jama Psychiatry. 71: 1350-63. PMID 25321337 DOI: 10.1001/Jamapsychiatry.2014.1314  0.109
2008 Lau G, Assunção-Talbott S, Crandall D, Eudicone JM, Pikalov A, Whitehead R, Carson WH, Kane JM. THE EFFICACY OF ARIPIPRAZOLE IN THE TREATMENT OF MULTIPLE SCHIZOPHRENIA SYMPTOMS DOMAINS: A POOLED ANALYSIS OF DATA FROM PIVOTAL TRIALS Schizophrenia Research. 102: 267. DOI: 10.1016/S0920-9964(08)70804-1  0.109
2016 Kane JM, Correll CU. The Role of Clozapine in Treatment-Resistant Schizophrenia. Jama Psychiatry. PMID 26841681 DOI: 10.1001/jamapsychiatry.2015.2966  0.109
2007 Turner M, Masand P, Roca M, Kane J. P.3.c.054 Results of a study on psychiatrists' perceptions of adherence to medication among patients with schizophrenia: the ADHES survey European Neuropsychopharmacology. 17: S455-S456. DOI: 10.1016/S0924-977X(07)70691-0  0.109
2003 Carlson CD, Cavazzoni PA, Berg PH, Wei H, Beasley CM, Kane JM. An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. The Journal of Clinical Psychiatry. 64: 898-906. PMID 12927004 DOI: 10.4088/JCP.V64N0807  0.109
2012 Manu P, Sarpal D, Muir O, Kane JM, Correll CU. When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. Schizophrenia Research. 134: 180-6. PMID 22113154 DOI: 10.1016/j.schres.2011.10.014  0.109
2012 Kane JM. Assessing and measuring nonresponse in schizophrenia. The Journal of Clinical Psychiatry. 73: e04. PMID 22316583 DOI: 10.4088/JCP.11076tx1c  0.109
2008 Betensky JD, Robinson DG, Gunduz-Bruce H, Sevy S, Lencz T, Kane JM, Malhotra AK, Miller R, McCormack J, Bilder RM, Szeszko PR. Patterns of stress in schizophrenia. Psychiatry Research. 160: 38-46. PMID 18514323 DOI: 10.1016/j.psychres.2007.06.001  0.109
2015 Silveira ASdA, Rocha DMLV, Attüx CRdF, Daltio CS, da Silva LA, Elkis H, Kane JM, Bressan RA. Patterns of clozapine and other antipsychotics prescriptions in patients with treatment-resistant schizophrenia in community mental health centers in São Paulo, Brazil Revista De Psiquiatria Clinica. 42: 165-170. DOI: 10.1590/0101-60830000000069  0.109
2006 Lencz T, Robinson DG, Xu K, Ekholm J, Sevy S, Gunduz-Bruce H, Woerner MG, Kane JM, Goldman D, Malhotra AK. DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. The American Journal of Psychiatry. 163: 529-31. PMID 16513877 DOI: 10.1176/Appi.Ajp.163.3.529  0.109
2000 Lencz T, Bilder R, Ashtari M, Szeszko P, Gunduz H, Schooler N, Robinson D, Woerner M, Becker J, Kane J. 330. Atypical antipsychotic effects on fMRI in drug-naive schizophrenia Biological Psychiatry. 47: S99. DOI: 10.1016/S0006-3223(00)00594-1  0.109
2021 Kane JM, Durgam S, Satlin A, Vanover KE, Chen R, Davis R, Mates S. Safety and tolerability of lumateperone for the treatment of schizophrenia: a pooled analysis of late-phase placebo- and active-controlled clinical trials. International Clinical Psychopharmacology. PMID 34054112 DOI: 10.1097/YIC.0000000000000371  0.108
2021 Belkin MR, Briggs MC, Candan K, Risola K, Kane JM, Birnbaum ML. Psychoeducation for Inpatients With First-Episode Psychosis: Results From a Survey of Psychiatry Trainees in New York City. Psychiatric Services (Washington, D.C.). appips201900633. PMID 33691485 DOI: 10.1176/appi.ps.201900633  0.108
2017 Rubio JM, Kane JM. Psychosis breakthrough on antipsychotic maintenance medication (BAMM): what can we learn? Npj Schizophrenia. 3: 36. PMID 29021565 DOI: 10.1038/s41537-017-0039-z  0.108
2013 Kane JM. Tools to assess negative symptoms in schizophrenia. The Journal of Clinical Psychiatry. 74: e12. PMID 23842020 DOI: 10.4088/JCP.12045tx2c  0.108
2001 Sevy S, Robinson DG, Holloway S, Alvir JM, Woerner MG, Bilder R, Goldman R, Lieberman J, Kane J. Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder Acta Psychiatrica Scandinavica. 104: 367-374. PMID 11722318 DOI: 10.1034/J.1600-0447.2001.00452.X  0.108
1996 Kane JM. Factors which can make Patients Difficult to Treat British Journal of Psychiatry. 169: 10-14. DOI: 10.1192/S0007125000298565  0.108
2008 Sevy S, Robinson DG, Holloway S, Alvir JM, Woerner MG, Bilder R, Goldman R, Lieberman J, Kane J. Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder Acta Psychiatrica Scandinavica. 104: 367-374. DOI: 10.1111/J.1600-0447.2001.00452.X  0.108
2013 Kane JM, Perlis RH, DiCarlo LA, Au-Yeung K, Duong J, Petrides G. First experience with a wireless system incorporating physiologic assessments and direct confirmation of digital tablet ingestions in ambulatory patients with schizophrenia or bipolar disorder. The Journal of Clinical Psychiatry. 74: e533-40. PMID 23842023 DOI: 10.4088/Jcp.12M08222  0.108
2017 Reinertsen E, Osipov M, Liu C, Kane JM, Petrides G, Clifford GD. Continuous assessment of schizophrenia using heart rate and accelerometer data. Physiological Measurement. 38: 1456-1471. PMID 28653659 DOI: 10.1088/1361-6579/Aa724D  0.108
2015 Buckley PF, Schooler NR, Goff DC, Hsiao J, Kopelowicz A, Lauriello J, Manschreck T, Mendelowitz AJ, Miller del D, Severe JB, Wilson DR, Ames D, Bustillo J, Mintz J, Kane JM, et al. Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study. Schizophrenia Bulletin. 41: 449-59. PMID 24870446 DOI: 10.1093/Schbul/Sbu067  0.108
2008 Helldin L, Kane J, Karilampi U, Norlander T, Archer T. Experience of quality of life and attitude to care and treatment in patients with schizophrenia: Role of cross-sectional remission. International Journal of Psychiatry in Clinical Practice. 12: 97-104. PMID 24916619 DOI: 10.1080/13651500701660007  0.108
2009 Fijal BA, Kinon BJ, Kapur S, Stauffer VL, Conley RR, Jamal HH, Kane JM, Witte MM, Houston JP. Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia Pharmacogenomics Journal. 9: 311-318. PMID 19451915 DOI: 10.1038/tpj.2009.24  0.108
1997 Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ, Sebree TB, Wallin BA, Kashkin KB. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia American Journal of Psychiatry. 154: 782-791. PMID 9167505 DOI: 10.1176/Ajp.154.6.782  0.108
2020 Kishimoto T, Hagi K, Kane J, Correll C. P.556 Long-acting injectable vs. oral antipsychotics for preventing rehospitalisation in schizophrenia: a meta-analysis of randomised, mirror-image, and cohort studies European Neuropsychopharmacology. 40: S315-S316. DOI: 10.1016/j.euroneuro.2020.09.407  0.108
2015 Lopez LV, Kane JM. Recommendations for the monitoring of serum concentrations of antipsychotic drugs in the treatment of schizophrenia. The Journal of Clinical Psychiatry. 76: 1249-50. PMID 26455671 DOI: 10.4088/JCP.15ac10243  0.107
1996 Chakos MH, Alvir JMJ, Woerner MG, Koreen A, Geisler S, Mayerhoff D, Sobel S, Kane JM, Borenstein M, Lieberman JA. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia Archives of General Psychiatry. 53: 313-319. PMID 8634009 DOI: 10.1001/Archpsyc.1996.01830040049009  0.107
2008 Kane JM, Lauriello J, Laska E, Di Marino M, Wolfgang CD. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. Journal of Clinical Psychopharmacology. 28: S29-35. PMID 18334910 DOI: 10.1097/JCP.0b013e318169cca7  0.107
2020 Schoretsanitis G, Mendelowitz A, Malur C, Braga RJ, Schooler NR, John M, de Leon J, Kane JM, Petrides G. Lack of ECT effects on clozapine plasma levels in patients with treatment-resistant schizophrenia: Pharmacokinetic evidence from a randomized clinical trial. Schizophrenia Research. PMID 32107101 DOI: 10.1016/j.schres.2020.02.008  0.107
2019 Rubio JM, Taipale H, Correll CU, Tanskanen A, Kane JM, Tiihonen J. Psychosis breakthrough on antipsychotic maintenance: results from a nationwide study. Psychological Medicine. 1-12. PMID 31190660 DOI: 10.1017/S0033291719001296  0.107
2006 DeRosse P, Funke B, Burdick KE, Lencz T, Goldberg TE, Kane JM, Kucherlapati R, Malhotra AK. COMT genotype and manic symptoms in schizophrenia. Schizophrenia Research. 87: 28-31. PMID 16828262 DOI: 10.1016/J.Schres.2006.06.008  0.107
2014 Vernon JA, Grudnikoff E, Seidman AJ, Frazier TW, Vemulapalli MS, Pareek P, Goldberg TE, Kane JM, Correll CU. Antidepressants for cognitive impairment in schizophrenia--a systematic review and meta-analysis. Schizophrenia Research. 159: 385-94. PMID 25240772 DOI: 10.1016/J.Schres.2014.08.015  0.107
2010 Kane JM, Strom BL, Eng SM, Faich G, Reynolds RF, D'Agostino RB, Ruskin J, Geier J, Karayal ON, Kremer C. PRIMARY AND READJUDICATION MORTALITY RESULTS FROM ZODIAC, A LARGE SIMPLE TRIAL OF ZIPRASIDONE VS. OLANZAPINE IN PATIENTS WITH SCHIZOPHRENIA Schizophrenia Research. 117: 183-184. DOI: 10.1016/J.Schres.2010.02.227  0.107
2011 Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials. Schizophrenia Research. 127: 83-92. PMID 21257294 DOI: 10.1016/j.schres.2010.11.020  0.107
2020 Siskind D, Honer WG, Clark S, Correll CU, Hasan A, Howes O, Kane JM, Kelly DL, Laitman R, Lee J, MacCabe JH, Myles N, Nielsen J, Schulte PF, Taylor D, et al. Consensus statement on the use of clozapine during the COVID-19 pandemic. Journal of Psychiatry & Neuroscience : Jpn. 45: 200061. PMID 32297722 DOI: 10.1503/Jpn.200061  0.106
1997 Marder SR, Kane JM, Schooler NR, Wirshing WC, Baker R, Ames D, Umbricht D, Ganguli R, Borenstein M. Effectiveness of clozapine in treatment resistant schizophrenia Schizophrenia Research. 24: 187. DOI: 10.1016/S0920-9964(97)82533-9  0.106
2016 Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJ, Birnbaum ML, Bloomfield MA, Bressan RA, Buchanan RW, Carpenter WT, Castle DJ, Citrome L, Daskalakis ZJ, Davidson M, Drake RJ, ... ... Kane J, et al. Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. The American Journal of Psychiatry. appiajp201616050503. PMID 27919182 DOI: 10.1176/Appi.Ajp.2016.16050503  0.106
2005 Ashtari M, Kumra S, Bhaskar SL, Clarke T, Thaden E, Cervellione KL, Rhinewine J, Kane JM, Adesman A, Milanaik R, Maytal J, Diamond A, Szeszko P, Ardekani BA. Attention-deficit/hyperactivity disorder: a preliminary diffusion tensor imaging study. Biological Psychiatry. 57: 448-55. PMID 15737658 DOI: 10.1016/j.biopsych.2004.11.047  0.106
2021 Rubio JM, Lencz T, Barber A, Moyett A, Ali S, Bassaw F, Ventura G, Germano N, Malhotra AK, Kane JM. Striatal functional connectivity in psychosis relapse: A hypothesis generating study. Schizophrenia Research. PMID 34183210 DOI: 10.1016/j.schres.2021.06.010  0.106
2018 Galling B, Vernon JA, Pagsberg AK, Wadhwa A, Grudnikoff E, Seidman AJ, Tsoy-Podosenin M, Poyurovsky M, Kane JM, Correll CU. Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia. Acta Psychiatrica Scandinavica. 137: 187-205. PMID 29431197 DOI: 10.1111/acps.12854  0.106
2009 Correll CU, Frederickson AM, Kane JM, Manu P. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disorders. 10: 788-97. PMID 19032710 DOI: 10.1111/j.1399-5618.2008.00625.x  0.106
2015 Zhang JP, Robinson DG, Gallego JA, John M, Yu J, Addington J, Tohen M, Kane JM, Malhotra AK, Lencz T. Association of a Schizophrenia Risk Variant at the DRD2 Locus With Antipsychotic Treatment Response in First-Episode Psychosis. Schizophrenia Bulletin. PMID 26320194 DOI: 10.1093/Schbul/Sbv116  0.105
1997 Kane JM. The New Antipsychotics Journal of Psychiatric Practice. 3: 343-355. DOI: 10.1097/00131746-199711000-00003  0.105
2020 Schooler N, Robinson D, Marcy P, Homan P, Achtyes E, Kane JM. O9.7. TECHNOLOGY ASSISTED RELAPSE PREVENTION PROGRAM REDUCES HOSPITALIZATION IN SCHIZOPHRENIA PATIENTS AT HIGH RISK FOR RELAPSE Schizophrenia Bulletin. 46: S23-S24. DOI: 10.1093/schbul/sbaa028.054  0.105
2006 DeRosse P, Funke B, Burdick KE, Lencz T, Ekholm JM, Kane JM, Kucherlapati R, Malhotra AK. Dysbindin genotype and negative symptoms in schizophrenia. The American Journal of Psychiatry. 163: 532-4. PMID 16513878 DOI: 10.1176/Appi.Ajp.163.3.532  0.105
2016 Cascio NL, Saba R, Hauser M, Vernal DL, Al-Jadiri A, Borenstein Y, Sheridan EM, Kishimoto T, Armando M, Vicari S, Nastro PF, Girardi P, Gebhardt E, Kane JM, Auther A, et al. Attenuated psychotic and basic symptom characteristics in adolescents with ultra-high risk criteria for psychosis, other non-psychotic psychiatric disorders and early-onset psychosis. European Child & Adolescent Psychiatry. PMID 26921232 DOI: 10.1007/s00787-016-0832-7  0.105
2016 Kane J, Emsley R, Correll C, Agid O, Arango C, Cahn W, Gorwood P, Haddad P, Heres S, Lambert M, Newton R, Stoevelaar H. The appropriate pharmacological management of recent-onset schizophrenia: an international panel study using the RAND/UCLA methodology European Neuropsychopharmacology. 26: S547-S548. DOI: 10.1016/S0924-977X(16)31591-7  0.105
2008 Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Sniadecki JL, Kane JM. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophrenia Research. 102: 230-40. PMID 18423985 DOI: 10.1016/j.schres.2008.02.021  0.105
1997 Tamminga CA, Kane JM. Olanzapine (Zyprexa):characteristics of a new antipsychotic. Expert Opinion On Investigational Drugs. 6: 1743-1752. PMID 15989578 DOI: 10.1517/13543784.6.11.1743  0.105
2013 Lencz T, Guha S, Liu C, Rosenfeld J, Mukherjee S, DeRosse P, John M, Cheng L, Zhang C, Badner JA, Ikeda M, Iwata N, Cichon S, Rietschel M, Nöthen MM, ... ... Kane JM, et al. Genome-wide association study implicates NDST3 in schizophrenia and bipolar disorder. Nature Communications. 4: 2739. PMID 24253340 DOI: 10.1038/Ncomms3739  0.104
2015 Carbon M, Kapoor S, Sheridan E, Al-Jadiri A, Azzo S, Sarkaria T, Kane JM, Saito E, Correll CU. Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics. Journal of the American Academy of Child and Adolescent Psychiatry. 54: 718-727.e3. PMID 26299293 DOI: 10.1016/j.jaac.2015.06.015  0.104
2011 Woerner MG, Correll CU, Alvir JM, Greenwald B, Delman H, Kane JM. Incidence of tardive dyskinesia with risperidone or olanzapine in the elderly: results from a 2-year, prospective study in antipsychotic-naïve patients. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 36: 1738-46. PMID 21508932 DOI: 10.1038/npp.2011.55  0.104
2010 Sevy S, Robinson DG, Napolitano B, Patel RC, Gunduz-Bruce H, Miller R, McCormack J, Lorell BS, Kane J. Are cannabis use disorders associated with an earlier age at onset of psychosis? A study in first episode schizophrenia. Schizophrenia Research. 120: 101-7. PMID 20471224 DOI: 10.1016/j.schres.2010.03.037  0.104
2012 Evins AE, Green AI, Kane JM, Murray RM. The effect of marijuana use on the risk for schizophrenia. The Journal of Clinical Psychiatry. 73: 1463-8. PMID 23218162 DOI: 10.4088/Jcp.12012Co1C  0.104
2009 Casey DE, Daniel DG, Tamminga C, Kane JM, Tran-Johnson T, Wozniak P, Abi-Saab W, Baker J, Redden L, Greco N, Saltarelli M. Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 34: 1330-8. PMID 19052541 DOI: 10.1038/Npp.2008.209  0.104
2020 Kane JM, Schooler NR, Marcy P, Correll CU, Achtyes ED, Gibbons RD, Robinson DG. Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia: A Randomized Clinical Trial. Jama Psychiatry. PMID 32667636 DOI: 10.1001/jamapsychiatry.2020.2076  0.104
2003 Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: Efficacy and safety of the first long-acting atypical antipsychotic American Journal of Psychiatry. 160: 1125-1132. PMID 12777271 DOI: 10.1176/appi.ajp.160.6.1125  0.104
2014 Kane JM, Zhao C, Johnson B, Baker RA, Eramo A, McQuade R, Duca A, Sanchez R, Peters-Strickland T. P.3.d.037 Effects of aripiprazole once-monthly in patients with schizophrenia switched from oral antipsychotics to aripiprazole once-monthly European Neuropsychopharmacology. 24. DOI: 10.1016/S0924-977X(14)70870-3  0.104
2004 Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. The American Journal of Psychiatry. 161: 414-25. PMID 14992963 DOI: 10.1176/APPI.AJP.161.3.414  0.104
2014 Fleischhacker WW, Kane JM, Geier J, Karayal O, Kolluri S, Eng SM, Reynolds RF, Strom BL. Completed and attempted suicides among 18,154 subjects with schizophrenia included in a large simple trial. The Journal of Clinical Psychiatry. 75: e184-90. PMID 24717389 DOI: 10.4088/Jcp.13M08563  0.103
2014 Ifteni P, Nielsen J, Burtea V, Correll CU, Kane JM, Manu P. Effectiveness and safety of rapid clozapine titration in schizophrenia. Acta Psychiatrica Scandinavica. 130: 25-9. PMID 24354448 DOI: 10.1111/acps.12241  0.103
1999 Tollefson GD, Dellva MA, Mattler CA, Kane JM, Wirshing DA, Kinon BJ, Ames D, Cohn CK, Daniel DG, Clark SC, Horne RL, Levine R, Miller M, Nemeroff CB, Reinstein MR, et al. Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo Journal of Clinical Psychopharmacology. 19: 435-443. PMID 10505585 DOI: 10.1097/00004714-199910000-00007  0.103
2014 Kane JM, Correll CU, Harvey PD, Olfson M. Clinical and Cost Implications of Treating Schizophrenia The Journal of Clinical Psychiatry. 75: e20. DOI: 10.4088/Jcp.13050Ip1  0.103
2013 Kishimoto T, Watanabe K, Uchida H, Mimura M, Kane JM, Correll CU. Antipsychotic polypharmacy: a Japanese survey of prescribers' attitudes and rationales. Psychiatry Research. 209: 406-11. PMID 23602697 DOI: 10.1016/j.psychres.2013.03.014  0.103
2011 Kane J. C.05.03 The role of novel atypical depot formulations in helping to improve long-term outcomes in schizophrenia European Neuropsychopharmacology. 21: S627. DOI: 10.1016/S0924-977X(11)71028-8  0.103
2005 Kumra S, Ashtari M, Cervellione KL, Henderson I, Kester H, Roofeh D, Wu J, Clarke T, Thaden E, Kane JM, Rhinewine J, Lencz T, Diamond A, Ardekani BA, Szeszko PR. White matter abnormalities in early-onset schizophrenia: a voxel-based diffusion tensor imaging study. Journal of the American Academy of Child and Adolescent Psychiatry. 44: 934-41. PMID 16113622 DOI: 10.1097/01.chi.0000170553.15798.94  0.103
2020 Kane JM, Vanover KE, Durgam S, Davis R, Satlin A, Rowe W, Mates S, Tamminga C. 185 The Safety and Tolerability of Lumateperone 42 mg for the Treatment of Schizophrenia: A Pooled Analysis of 3 Randomized Placebo-Controlled Trials. Cns Spectrums. 25: 316-317. PMID 32331042 DOI: 10.1017/S1092852920001005  0.103
2019 Homan P, Argyelan M, DeRosse P, Szeszko P, Gallego JA, Hanna L, Robinson D, Kane JM, Lencz T, Malhotra AK. Structural similarity networks predict clinical outcome in early-phase psychosis. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 30679724 DOI: 10.1038/S41386-019-0322-Y  0.103
2007 Hodgkinson CA, Goldman D, Ducci F, DeRosse P, Caycedo DA, Newman ER, Kane JM, Roy A, Malhotra AK. The FEZ1 gene shows no association to schizophrenia in Caucasian or African American populations. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 32: 190-6. PMID 16936715 DOI: 10.1038/Sj.Npp.1301177  0.102
2013 Peters-Strickland T, Fleischhacker W, Sanchez R, Jin N, Baker R, Johnson B, Loze J, McQuade R, Carson W, Kane J. P.3.d.027 Aripiprazole once-monthly for schizophrenia: a double-blind, randomised, non-inferiority study versus oral aripiprazole European Neuropsychopharmacology. 23: S473-S474. DOI: 10.1016/S0924-977X(13)70750-8  0.102
2019 Van Meter AR, Birnbaum ML, Rizvi A, Kane JM. Online help-seeking prior to diagnosis: Can web-based resources reduce the duration of untreated mood disorders in young people? Journal of Affective Disorders. 252: 130-134. PMID 30981056 DOI: 10.1016/j.jad.2019.04.019  0.102
2016 Correll CU, Skuban A, Hobart M, Ouyang J, Weiller E, Weiss C, Kane JM. Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studies. Schizophrenia Research. PMID 27157799 DOI: 10.1016/j.schres.2016.04.012  0.102
2018 Correll CU, Galling B, Pawar A, Krivko A, Bonetto C, Ruggeri M, Craig TJ, Nordentoft M, Srihari VH, Guloksuz S, Hui CLM, Chen EYH, Valencia M, Juarez F, Robinson DG, ... ... Kane JM, et al. Comparison of Early Intervention Services vs Treatment as Usual for Early-Phase Psychosis: A Systematic Review, Meta-analysis, and Meta-regression. Jama Psychiatry. PMID 29800949 DOI: 10.1001/Jamapsychiatry.2018.0623  0.102
2004 Hodgkinson CA, Goldman D, Jaeger J, Persaud S, Kane JM, Lipsky RH, Malhotra AK. Disrupted in schizophrenia 1 (DISC1): association with schizophrenia, schizoaffective disorder, and bipolar disorder. American Journal of Human Genetics. 75: 862-72. PMID 15386212 DOI: 10.1086/425586  0.102
2017 Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis. The Journal of Clinical Psychiatry. PMID 28146614 DOI: 10.4088/JCP.16r10832  0.102
2020 Bhidayasiri R, Kane JM, Frei KP, Caroff SN, Correll CU, Fahn S, Jankovic J, Hauser RA, Truong DD. Expanding phenomenologic heterogeneity of tardive syndromes: Time for an updated assessment tool. Parkinsonism & Related Disorders. 77: 141-145. PMID 32823151 DOI: 10.1016/j.parkreldis.2020.06.023  0.102
2003 Szeszko PR, Goldberg E, Gunduz-Bruce H, Ashtari M, Robinson D, Malhotra AK, Lencz T, Bates J, Crandall DT, Kane JM, Bilder RM. Smaller anterior hippocampal formation volume in antipsychotic-naive patients with first-episode schizophrenia. The American Journal of Psychiatry. 160: 2190-7. PMID 14638589 DOI: 10.1176/Appi.Ajp.160.12.2190  0.101
2007 DeRosse P, Hodgkinson CA, Lencz T, Burdick KE, Kane JM, Goldman D, Malhotra AK. Disrupted in schizophrenia 1 genotype and positive symptoms in schizophrenia. Biological Psychiatry. 61: 1208-10. PMID 17054920 DOI: 10.1016/J.Biopsych.2006.07.023  0.101
2000 Kane J. The criteria for evaluating response to antipsychotics in schizophrenia European Neuropsychopharmacology. 10: 129-130. DOI: 10.1016/S0924-977X(00)80026-7  0.101
1995 Kronig MH, Munne RA, Szymanski S, Safferman AZ, Pollack S, Cooper T, Kane JM, Lieberman JA. Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients American Journal of Psychiatry. 152: 179-182. PMID 7840349 DOI: 10.1176/Ajp.152.2.179  0.101
2016 Browne J, Penn DL, Meyer-Kalos PS, Mueser KT, Estroff SE, Brunette MF, Correll CU, Robinson J, Rosenheck RA, Schooler N, Robinson DG, Addington J, Marcy P, Kane JM. Psychological well-being and mental health recovery in the NIMH RAISE early treatment program. Schizophrenia Research. PMID 27913160 DOI: 10.1016/J.Schres.2016.11.032  0.101
2012 Pikalov A, Loebel A, Cucchiaro J, Xu J, Sarma K, Kane J. P.3.c.041 Relapse prevention in schizophrenia: 12 month treatment with lurasidone versus quetiapine extended release among responders to acute treatment European Neuropsychopharmacology. 22: S340-S341. DOI: 10.1016/S0924-977X(12)70525-4  0.101
2012 Kishi T, Fukuo Y, Okochi T, Kawashima K, Kitajima T, Inada T, Ozaki N, Musso GM, Kane JM, Correll CU, Iwata N. Serotonin 6 receptor gene and schizophrenia: case-control study and meta-analysis. Human Psychopharmacology. 27: 63-9. PMID 22745941 DOI: 10.1002/hup.1266  0.101
2014 Kane JM, Zhao C, Johnson B, Baker RA, Eramo A, McQuade RD, Duca A, Sanchez R, Peters-Strickland T. P.3.d.034 Effects of aripiprazole once-monthly on functioning in patients with schizophrenia European Neuropsychopharmacology. 24. DOI: 10.1016/S0924-977X(14)70867-3  0.101
2005 Leucht S, Busch R, Hamann J, Kissling W, Kane JM. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biological Psychiatry. 57: 1543-9. PMID 15953491 DOI: 10.1016/j.biopsych.2005.02.023  0.101
2016 Al-Dhaher Z, Kapoor S, Saito E, Krakower S, David L, Ake T, Kane JM, Correll CU, Carbon M. Activating and Tranquilizing Effects of First-Time Treatment with Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Youth. Journal of Child and Adolescent Psychopharmacology. PMID 27093218 DOI: 10.1089/cap.2015.0141  0.101
2020 Potkin SG, Kane JM, Correll CU, Lindenmayer JP, Agid O, Marder SR, Olfson M, Howes OD. The Neurobiology of Treatment-Resistant Schizophrenia: Paths to Antipsychotic Resistance and A Roadmap for Future Research. Focus (American Psychiatric Publishing). 18: 456-465. PMID 33343259 DOI: 10.1176/appi.focus.18309  0.1
1996 Barnes TR, Kane JM. Choosing between old and new antipsychotics Current Opinion in Psychiatry. 9: 41-44. DOI: 10.1097/00001504-199601000-00008  0.1
1995 Kane JM. Dosing issues and depot medication in the maintenance treatment of schizophrenia International Clinical Psychopharmacology. 10: 65-72. DOI: 10.1097/00004850-199509003-00009  0.1
1995 Kane JM. Dosing issues and depot medication in the maintenance treatment of schizophrenia International Clinical Psychopharmacology. 10: 65-71. DOI: 10.1097/00004850-199509000-00009  0.1
2014 Ifteni P, Correll CU, Burtea V, Kane JM, Manu P. Sudden unexpected death in schizophrenia: autopsy findings in psychiatric inpatients. Schizophrenia Research. 155: 72-6. PMID 24704220 DOI: 10.1016/j.schres.2014.03.011  0.1
2013 Marder SR, Alphs L, Anghelescu IG, Arango C, Barnes TR, Caers I, Daniel DG, Dunayevich E, Fleischhacker WW, Garibaldi G, Green MF, Harvey PD, Kahn RS, Kane JM, Keefe RS, et al. Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia. Schizophrenia Research. 150: 328-33. PMID 24028744 DOI: 10.1016/J.Schres.2013.07.058  0.1
2015 Loebel A, Silva R, Goldman R, Watabe K, Pikalov A, Cucchiaro J, Kane J. P.3.d.037 Optimising response to lurasidone in patients with acute schizophrenia: A randomised, double-blind, placebo-controlled study of dosing regimens European Neuropsychopharmacology. 25: S500. DOI: 10.1016/S0924-977X(15)30685-4  0.1
2013 Kane J, Citrome L, Litman R, Zukin S, Lu K, Ruth A, Nagy K, Laszlovszky I, Durgam S. P.3.d.007 Efficacy of cariprazine on PANSS items and Marder factors: post hoc analysis of a double-blind, placebo-controlled trial in schizophrenia European Neuropsychopharmacology. 23: S461-S462. DOI: 10.1016/S0924-977X(13)70730-2  0.1
2004 Funke B, Finn CT, Plocik AM, Lake S, DeRosse P, Kane JM, Kucherlapati R, Malhotra AK. Association of the DTNBP1 locus with schizophrenia in a U.S. population. American Journal of Human Genetics. 75: 891-8. PMID 15362017 DOI: 10.1086/425279  0.1
2017 Kane J. Clinical presentation of treatment-resistant schizophrenia (TRS) European Neuropsychopharmacology. 27: S1135. DOI: 10.1016/S0924-977X(17)31965-X  0.1
2008 Detke H, McDonnell D, Kane J, Naber D, Sethuraman G, Lin D. P.3.a.015 Efficacy and safety of olanzapine long-acting injection for maintenance treatment of schizophrenia European Neuropsychopharmacology. 18: S393-S394. DOI: 10.1016/S0924-977X(08)70568-6  0.1
2009 Helldin L, Kane JM, Hjärthag F, Norlander T. The importance of cross-sectional remission in schizophrenia for long-term outcome: a clinical prospective study. Schizophrenia Research. 115: 67-73. PMID 19666215 DOI: 10.1016/j.schres.2009.07.004  0.1
2015 Grudnikoff E, Soto EC, Frederickson A, Birnbaum ML, Saito E, Dicker R, Kane JM, Correll CU. Suicidality and hospitalization as cause and outcome of pediatric psychiatric emergency room visits. European Child & Adolescent Psychiatry. 24: 797-814. PMID 25331538 DOI: 10.1007/s00787-014-0624-x  0.099
2019 Correll CU, Kane JM. Ranking Antipsychotics for Efficacy and Safety in Schizophrenia. Jama Psychiatry. PMID 31693073 DOI: 10.1001/jamapsychiatry.2019.3377  0.099
1994 Kane JM. Newer antipsychotic drugs. A review of their pharmacology and therapeutic potential. Drugs. 46: 585-93. PMID 7506647 DOI: 10.2165/00003495-199346040-00002  0.099
2016 Nosaka T, Hagi K, Pikalov A, Loebel A, Kane J. Efficacy of lurasidone in schizophrenia: a systematic review and meta-analysis of short-term trials utilizing active comparator European Neuropsychopharmacology. 26: S580. DOI: 10.1016/S0924-977X(16)31642-X  0.099
1997 Kane JM. The use of scales for clinical monitoring of disease progression and the treatment of schizophrenia. Neuropsychobiology. 35: 64-6. PMID 9097294 DOI: 10.1159/000119391  0.099
2005 Gerson S, Athanasiou M, Reed CR, Dain B, Carr J, Whalen H, Lachowicz M, Malhotra A, Kane J. Discovery of Genetic Markers Associated with Clozapine Induced Agranulocytosis. Blood. 106: 3074-3074. DOI: 10.1182/Blood.V106.11.3074.3074  0.099
2017 Blanco EA, Duque LM, Rachamallu V, Yuen E, Kane JM, Gallego JA. Predictors of aggression in 3.322 patients with affective disorders and schizophrenia spectrum disorders evaluated in an emergency department setting. Schizophrenia Research. PMID 29102223 DOI: 10.1016/j.schres.2017.10.002  0.099
2004 Alphs L, Anand R, Islam MZ, Meltzer HY, Kane JM, Krishnan R, Green AI, Potkin S, Chouinard G, Lindenmayer JP, Kerwin R. The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients. Schizophrenia Bulletin. 30: 577-86. PMID 15631247 DOI: 10.1093/Oxfordjournals.Schbul.A007102  0.098
2019 Kane J, Vanover K, Durgam S, Weingart M, Davis R, Satlin A, Tamminga C. P.671 Efficacy and safety of lumateperone tosylate 42mg in the treatment of schizophrenia: A pooled analysis of phase 2 and 3 studies European Neuropsychopharmacology. 29: S453-S454. DOI: 10.1016/j.euroneuro.2019.09.642  0.098
2007 Leucht S, Kane JM. Measurement-based psychiatry: definitions of response, remission, stability, and relapse in schizophrenia. The Journal of Clinical Psychiatry. 67: 1813-4. PMID 17196063 DOI: 10.4088/JCP.V67N1120  0.098
2019 Schoretsanitis G, Kane JM, Ruan CJ, Spina E, Hiemke C, de Leon J. A comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adult patients. Expert Review of Clinical Pharmacology. PMID 31075044 DOI: 10.1080/17512433.2019.1617695  0.098
2019 Kane J, Marder S, Lindenmayer J, Jimenez R, Farahmand K, Siegert S. O12.6. LONG-TERM EFFECTS OF VALBENAZINE ON TARDIVE DYSKINESIA IN PATIENTS WITH SCHIZOPHRENIA/SCHIZOAFFECTIVE DISORDER: RESULTS FROM AN OPEN-LABEL, ROLLOVER STUDY Schizophrenia Bulletin. 45: S199-S200. DOI: 10.1093/SCHBUL/SBZ021.270  0.098
2015 O'Grady MA, Kapoor S, Auerbach M, Morley J, Yu J, Salvas V, Neighbors C, Morgenstern J, Conigliaro J, Kwon N, McGinn T, Kane J. Building sustainable SBIRT in an integrated hospital system in New York Addiction Science & Clinical Practice. 10. DOI: 10.1186/1940-0640-10-S1-A44  0.098
2012 Kane JM, Cornblatt B, Correll CU, Goldberg T, Lencz T, Malhotra AK, Robinson D, Szeszko P. The field of schizophrenia: strengths, weaknesses, opportunities, and threats. Schizophrenia Bulletin. 38: 1-4. PMID 22102093 DOI: 10.1093/schbul/sbr131  0.098
2015 Correll CU, Skuban A, Hobart M, Ouyang J, Weiller E, Weiss C, Kane JM. Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studies Schizophrenia Research. DOI: 10.1016/j.schres.2016.04.012  0.098
2015 Kishimoto T, Hagi K, Nitta M, Leucht S, Kane J, Correll C. P.3.d.067 Long-acting injectable vs oral antipsychotics for hospitalisation prevention in schizophrenia: a systematic review/meta-analysis of cohort studies European Neuropsychopharmacology. 25: S519. DOI: 10.1016/S0924-977X(15)30715-X  0.097
2015 Kane JM, Zukin S, Wang Y, Lu K, Ruth A, Nagy K, Laszlovszky I, Durgam S. Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia: Results From an International, Phase III Clinical Trial. Journal of Clinical Psychopharmacology. 35: 367-73. PMID 26075487 DOI: 10.1097/JCP.0000000000000346  0.097
2018 Homan P, Argyelan M, Robinson D, Kane J, Lencz T, Malhotra A. F198. Parahippocampal Thickness Predicts Treatment Improvement in Early and Chronic Schizophrenia Biological Psychiatry. 83: S315-S316. DOI: 10.1016/j.biopsych.2018.02.812  0.097
2018 Baumel A, Baker J, Birnbaum ML, Christensen H, De Choudhury M, Mohr DC, Muench F, Schlosser D, Titov N, Kane JM. Summary of Key Issues Raised in the Technology for Early Awareness of Addiction and Mental Illness (TEAAM-I) Meeting. Psychiatric Services (Washington, D.C.). appips201700270. PMID 29334875 DOI: 10.1176/Appi.Ps.201700270  0.097
2014 Manu P, Khan S, Radhakrishnan R, Russ MJ, Kane JM, Correll CU. Body mass index identified as an independent predictor of psychiatric readmission. The Journal of Clinical Psychiatry. 75: e573-7. PMID 25004198 DOI: 10.4088/Jcp.13M08795  0.097
1980 Kane JM, Rifkin A, Quitkin F, Nayak D, Saraf K, Ramos-Lorenzi JR, Klein DF, Sachar EJ. Low dose fluphenazine decanoate in maintenance treatment of schizophrenia. Psychiatry Research. 1: 341-8. PMID 233160 DOI: 10.1016/0165-1781(79)90016-7  0.097
2019 Petrides G, Malur C, Braga RJ, Bailine SH, Schooler NR, Malhotra AK, Kane JM, Sanghani S, Goldberg TE, John M, Mendelowitz A. Electroconvulsive Therapy Augmentation in Clozapine-Resistant Schizophrenia: A Prospective, Randomized Study. Focus (American Psychiatric Publishing). 17: 76-82. PMID 32015718 DOI: 10.1176/appi.focus.17106  0.097
2020 Guinart D, de Filippis R, Rosson S, Prizgint L, Patil B, Talasazan N, Gibbons RD, Kane JM. O8.2. VALIDATION OF A COMPUTERIZED ADAPTIVE TESTING TOOL FOR PSYCHOSIS: THE CAT-PSYCHOSIS BATTERY Schizophrenia Bulletin. 46: S19-S19. DOI: 10.1093/schbul/sbaa028.043  0.097
2014 Li H, Luo J, ChuanyueWang, Xie S, Xu X, XiaopingWang, Yu W, Gu N, Kane JM. Corrigendum to "Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: A randomized, double-blind, active parallel-controlled, multicenter clinical trial" [Schizophr. Res. 157 (1-3) (August 2014) 112-119] (DOI:10.1016/j.schres.2014.05.040) Schizophrenia Research. DOI: 10.1016/j.schres.2014.07.035  0.097
2021 May SG, Huber C, Roach M, Shafrin J, Aubry W, Lakdawalla D, Kane JM, Forma F. Adoption of Digital Health Technologies in the Practice of Behavioral Health: Qualitative Case Study of Glucose Monitoring Technology. Journal of Medical Internet Research. 23: e18119. PMID 33533725 DOI: 10.2196/18119  0.097
2011 Kane JM. Transitioning from acute to long-term treatment in schizophrenia. The Journal of Clinical Psychiatry. 72: e10. PMID 21450146 DOI: 10.4088/JCP.9101tx1c  0.097
1998 Woerner MG, Alvir JMJ, Saltz BL, Lieberman JA, Kane JM. Prospective study of tardive dyskinesia in the elderly: Rates and risk factors American Journal of Psychiatry. 155: 1521-1528. PMID 9812112 DOI: 10.1176/Ajp.155.11.1521  0.096
2005 Szeszko PR, Lipsky R, Mentschel C, Robinson D, Gunduz-Bruce H, Sevy S, Ashtari M, Napolitano B, Bilder RM, Kane JM, Goldman D, Malhotra AK. Brain-derived neurotrophic factor val66met polymorphism and volume of the hippocampal formation. Molecular Psychiatry. 10: 631-6. PMID 15768049 DOI: 10.1038/Sj.Mp.4001656  0.096
2013 Kane J. C.04.01 Protecting patients from the long-term consequences of schizophrenia European Neuropsychopharmacology. 23: S632-S633. DOI: 10.1016/S0924-977X(13)71005-8  0.096
2008 Correll CU, Smith CW, Auther AM, McLaughlin D, Shah M, Foley C, Olsen R, Lencz T, Kane JM, Cornblatt BA. Predictors of remission, schizophrenia, and bipolar disorder in adolescents with brief psychotic disorder or psychotic disorder not otherwise specified considered at very high risk for schizophrenia. Journal of Child and Adolescent Psychopharmacology. 18: 475-90. PMID 18928412 DOI: 10.1089/cap.2007.110  0.096
2008 Kane J, Zhao J, Panagides J. Efficacy and safety of asenapine in patients with acute exacerbation of schizophrenia Schizophrenia Research. 98: 14. DOI: 10.1016/j.schres.2007.12.026  0.095
2018 Wang R, Wang W, Aung MH, Ben-Zeev D, Brian R, Campbell AT, Choudhury T, Hauser M, Kane J, Scherer EA, Walsh M. Predicting Symptom Trajectories of Schizophrenia Using Mobile Sensing Getmobile: Mobile Computing and Communications. 22: 32-37. DOI: 10.1145/3276145.3276157  0.095
2017 Wang R, Wang W, Aung MSH, Ben-Zeev D, Brian R, Campbell AT, Choudhury T, Hauser M, Kane J, Scherer EA, Walsh M. Predicting Symptom Trajectories of Schizophrenia using Mobile Sensing Proceedings of the Acm On Interactive, Mobile, Wearable and Ubiquitous Technologies. 1: 1-24. DOI: 10.1145/3130976  0.095
2011 Strom BL, Eng SM, Faich G, Reynolds RF, D'Agostino RB, Ruskin J, Kane JM. Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). The American Journal of Psychiatry. 168: 193-201. PMID 21041245 DOI: 10.1176/Appi.Ajp.2010.08040484  0.095
2019 Kirschenbaum MA, Birnbaum ML, Rizvi A, Muscat W, Patel L, Kane JM. Google search activity in early psychosis: A qualitative analysis of internet search query content in first episode psychosis. Early Intervention in Psychiatry. PMID 31637869 DOI: 10.1111/eip.12886  0.095
2017 Ben-Zeev D, Brian R, Wang R, Wang W, Campbell AT, Aung MS, Merrill M, Tseng VW, Choudhury T, Hauser M, Kane JM, Scherer EA. CrossCheck: Integrating Self-Report, Behavioral Sensing, and Smartphone Use to Identify Digital Indicators of Psychotic Relapse. Psychiatric Rehabilitation Journal. PMID 28368138 DOI: 10.1037/prj0000243  0.095
1990 Lieberman JA, Yunis J, Egea E, Canoso RT, Kane JM, Yunis EJ. HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Archives of General Psychiatry. 47: 945-8. PMID 2222133 DOI: 10.1001/Archpsyc.1990.01810220061007  0.095
2016 Galling B, Roldán A, Rietschel L, Hagi K, Walyzada F, Zheng W, Cao XL, Xiang YT, Kane JM, Correll CU. Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials. Expert Opinion On Drug Safety. PMID 26967126 DOI: 10.1517/14740338.2016.1165668  0.095
2014 Gallego JA, Rachamallu V, Yuen EY, Fink S, Duque LM, Kane JM. Predictors of suicide attempts in 3.322 patients with affective disorders and schizophrenia spectrum disorders Psychiatry Research. DOI: 10.1016/j.psychres.2015.05.024  0.095
2014 Baker R, Fleischhacker WW, Sanchez R, Tsai LF, Peters-Strickland T, Eramo A, Kostic D, Kane J. EPA-0790 – All-cause discontinuation and safety of aripiprazole once-monthly for the treatment of schizophrenia: A pooled analysis of two double-blind, randomized, controlled trials European Psychiatry. 29: 1. DOI: 10.1016/S0924-9338(14)78135-0  0.094
2012 Kishimoto T, Nitta M, Borenstein M, Kane J, Correll C. P.3.c.033 Long-acting injectable vs. oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image and cohort studies European Neuropsychopharmacology. 22: S335-S336. DOI: 10.1016/S0924-977X(12)70517-5  0.094
2015 Kane JM. The role of NMDA receptors in schizophrenia. The Journal of Clinical Psychiatry. 76: e1. PMID 25650674 DOI: 10.4088/JCP.13078tx5c  0.094
2013 Eramo A, Fleischhacker WW, Sanchez R, Perry P, Jin N, Johnson B, McQuade RD, Carson WH, Kane J. 2277 – A placebo-controlled study of efficacy and safety of aripiprazole once-monthly for long-term maintenance treatment in schizophrenia European Psychiatry. 28: 1. DOI: 10.1016/S0924-9338(13)77138-4  0.094
2014 Kane JM. Organizational Barriers to Using Long-Acting Injectable Antipsychotics in Practice The Journal of Clinical Psychiatry. 75: e16. DOI: 10.4088/JCP.13024TX1C  0.094
2012 Sanchez R, Perry P, Jin N, Johnson B, Forbes R, McQuade R, Carson W, Fleischhacker W, Kane J. P.3.c.018 A placebo-controlled study of efficacy/safety of aripiprazole intramuscular depot for long-term maintenance treatment of schizophrenia European Neuropsychopharmacology. 22: S327. DOI: 10.1016/S0924-977X(12)70502-3  0.094
2018 Correll CU, Cutler AJ, Kane JM, McEvoy JP, Liang GS, O'Brien CF. Characterizing Treatment Effects of Valbenazine for Tardive Dyskinesia: Additional Results From the KINECT 3 Study. The Journal of Clinical Psychiatry. 80. PMID 30695293 DOI: 10.4088/JCP.18m12278  0.094
1995 Kane JM. Current Problems With the Pharmacotherapy of Schizophrenia Clinical Neuropharmacology. 18: S154-S161. DOI: 10.1097/00002826-199501001-00017  0.094
2000 Lencz T, Bilder RM, Ashtari M, Szeszko P, Gunduz H, Schooler N, Robinson D, Woerner M, Becker J, Kane J. FMRI motor effects of atypical antipsychotics in drug-naive schizophrenia Neuroimage. 11: S195. DOI: 10.1016/S1053-8119(00)91128-5  0.094
2015 Kane J. C.05.03 Do current treatment options differ in terms of functioning and quality of life outcomes in schizophrenia? European Neuropsychopharmacology. 25: S666. DOI: 10.1016/S0924-977X(15)30951-2  0.093
1993 Szymanski S, Lieberman J, Pollack S, Kane J, Munne R, Umbricht D, Safferman A, Masiar S, Galkowski B. Gender differences in clozapine treated schizophrenic patients Schizophrenia Research. 9: 111. DOI: 10.1016/0920-9964(93)90149-D  0.093
2017 Silverman BL, Martin W, Memisoglu A, DiPetrillo L, Correll CU, Kane JM. A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers. Schizophrenia Research. PMID 29158012 DOI: 10.1016/j.schres.2017.10.014  0.093
2015 Argyelan M, Gallego JA, Robinson DG, Ikuta T, Sarpal D, John M, Kingsley PB, Kane J, Malhotra AK, Szeszko PR. Abnormal resting state FMRI activity predicts processing speed deficits in first-episode psychosis. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 40: 1631-9. PMID 25567423 DOI: 10.1038/npp.2015.7  0.093
2003 Kane JM, Krystal J, Correll CU. Treatment Models and Designs for Intervention Research During the Psychotic Prodrome Schizophrenia Bulletin. 29: 747-756. PMID 14989412 DOI: 10.1093/Oxfordjournals.Schbul.A007044  0.093
2015 Goldberg JF, Freeman MP, Balon R, Citrome L, Thase ME, Kane JM, Fava M. THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY SURVEY OF PSYCHOPHARMACOLOGISTS' PRACTICE PATTERNS FOR THE TREATMENT OF MOOD DISORDERS. Depression and Anxiety. 32: 605-13. PMID 26129956 DOI: 10.1002/da.22378  0.093
2021 Jackson R, Brams MN, Citrome L, Hoberg AR, Isaacson SH, Kane JM, Kumar R. Assessment of the Impact of Tardive Dyskinesia in Clinical Practice: Consensus Panel Recommendations. Neuropsychiatric Disease and Treatment. 17: 1589-1597. PMID 34079257 DOI: 10.2147/NDT.S310605  0.093
1995 Bellack AS, Schooler NR, Kane JM, Marder SR. The impact of clozapine on psychosocial competence Schizophrenia Research. 15: 143. DOI: 10.1016/0920-9964(95)95444-E  0.093
2010 Lencz T, Robinson DG, Napolitano B, Sevy S, Kane JM, Goldman D, Malhotra AK. DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia. Pharmacogenetics and Genomics. 20: 569-72. PMID 20664489 DOI: 10.1097/Fpc.0B013E32833Ca24B  0.092
2015 Mueser KT, Penn DL, Addington J, Brunette MF, Gingerich S, Glynn SM, Lynde DW, Gottlieb JD, Meyer-Kalos P, McGurk SR, Cather C, Saade S, Robinson DG, Schooler NR, Rosenheck RA, ... Kane JM, et al. The NAVIGATE Program for First-Episode Psychosis: Rationale, Overview, and Description of Psychosocial Components. Psychiatric Services (Washington, D.C.). 66: 680-90. PMID 25772766 DOI: 10.1176/Appi.Ps.201400413  0.092
2018 Kishimoto T, Hagi K, Nitta M, Leucht S, Olfson M, Kane JM, Correll CU. Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies. Schizophrenia Bulletin. 44: 603-619. PMID 29868849 DOI: 10.1093/schbul/sbx090  0.092
1992 Safferman AZ, Lieberman JA, Pollack S, Kane JM. Clozapine and akathisia Biological Psychiatry. 31: 753-754. PMID 1350924 DOI: 10.1016/0006-3223(92)90291-7  0.092
2003 McQuade R, Jody D, Kane J, Carson W, Kujawa M, Stringfellow J, Marcus R, Sanchez R, Meltzer H. P.2.105 Efficacy and safety of aripiprazole versus perphenazine in treatment-resistant schizophrenia European Neuropsychopharmacology. 13: S326. DOI: 10.1016/S0924-977X(03)92058-X  0.092
1983 LIEBERMAN JA, KANE JM. Questioning DST Normalization as a Guide to Tricyclic Discontinuation American Journal of Psychiatry. 140: 263-b-264. DOI: 10.1176/Ajp.140.2.263-B  0.092
2017 Rosenheck RA, Estroff SE, Sint K, Lin H, Mueser KT, Robinson DG, Schooler NR, Marcy P, Kane JM. Incomes and Outcomes: Social Security Disability Benefits in First-Episode Psychosis. The American Journal of Psychiatry. appiajp201716111273. PMID 28427286 DOI: 10.1176/Appi.Ajp.2017.16111273  0.092
1996 Szymanski S, Lieberman J, Pollack S, Kane JM, Safferman A, Munne R, Umbricht D, Woerner M, Masiar S, Kronig M. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics Biological Psychiatry. 39: 249-254. PMID 8645771 DOI: 10.1016/0006-3223(95)00138-7  0.092
1994 Kane JM, Freeman HL. Towards More Effective Antipsychotic Treatment British Journal of Psychiatry. 165: 22-31. DOI: 10.1192/S0007125000293173  0.092
1997 Kane JM. What Makes an Antipsychotic ‘Atypical’? Cns Drugs. 7: 347-348. DOI: 10.2165/00023210-199707050-00002  0.092
1988 LIEBERMAN J, POLLACK S, LESSER M, KANE J. Pharmacologic Characterization of Tardive Dyskinesia Journal of Clinical Psychopharmacology. 8: 254???260. DOI: 10.1097/00004714-198808000-00004  0.091
2014 Bressan R, Rocha D, Silveira A, Attux C, Daltio C, Silva L, Elkis H, Kane JM. Poster #M263 CLOZAPINE PRESCRIPTION TO TREATMENT-RESISTANT SCHIZOPHRENIA PATIENTS IN COMMUNITY MENTAL HEALTH SERVICES IN SãO PAULO BRAZIL Schizophrenia Research. 153: S286-S287. DOI: 10.1016/S0920-9964(14)70813-8  0.091
2009 Lencz T, Lipsky RH, DeRosse P, Burdick KE, Kane JM, Malhotra AK. Molecular differentiation of schizoaffective disorder from schizophrenia using BDNF haplotypes. The British Journal of Psychiatry : the Journal of Mental Science. 194: 313-8. PMID 19336781 DOI: 10.1192/Bjp.Bp.108.050401  0.091
2007 Kane JM. The management of schizophrenia: safety, treatment, and continuity of care. Introduction. Cns Spectrums. 12: 4. PMID 17934383 DOI: 10.1017/S1092852900026274  0.091
2021 Guinart D, Taipale H, Rubio JM, Tanskanen A, Correll CU, Tiihonen J, Kane JM. Risk Factors, Incidence, and Outcomes of Neuroleptic Malignant Syndrome on Long-Acting Injectable vs Oral Antipsychotics in a Nationwide Schizophrenia Cohort. Schizophrenia Bulletin. PMID 34013325 DOI: 10.1093/schbul/sbab062  0.091
2014 Fleischhacker WW, Baker RA, Eramo A, Sanchez R, Tsai LF, Peters-Strickland T, Perry PP, McQuade RD, Johnson BR, Carson WH, Kane JM. Effects of aripiprazole once-monthly on domains of personal and social performance: results from 2 multicenter, randomized, double-blind studies. Schizophrenia Research. 159: 415-20. PMID 25281992 DOI: 10.1016/J.Schres.2014.09.019  0.091
1985 Kane JM. Compliance issues in outpatient treatment. Journal of Clinical Psychopharmacology. 5: 22S-27S. PMID 2860139 DOI: 10.1097/00004714-198506001-00005  0.091
2012 Kane JM. Clozapine is underutilized. Shanghai Archives of Psychiatry. 24: 114-5. PMID 25324613 DOI: 10.3969/j.issn.1002-0829.2012.02.008  0.091
2015 Walling D, Marder SR, Kane J, Fleischhacker WW, Keefe RS, Hosford DA, Dvergsten C, Segreti AC, Beaver JS, Toler SM, Jett JE, Dunbar GC. Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia. Schizophrenia Bulletin. PMID 26071208 DOI: 10.1093/schbul/sbv072  0.09
2005 McGurk SR, Carter C, Goldman R, Green MF, Marder SR, Xie H, Schooler NR, Kane JM. The effects of clozapine and risperidone on spatial working memory in schizophrenia. The American Journal of Psychiatry. 162: 1013-6. PMID 15863811 DOI: 10.1176/Appi.Ajp.162.5.1013  0.09
2013 Kane J, Zhao J, Baker RA, Eramo A, McQuade RD, Sanchez R, Peters-Strickland T. P.3.d.037 Hospitalization rates in patients switched from oral antipsychotics to aripiprazole once-monthly for schizophrenia European Neuropsychopharmacology. 23. DOI: 10.1016/S0924-977X(13)70760-0  0.09
2016 Browne J, Edwards AN, Penn DL, Meyer-Kalos PS, Gottlieb JD, Julian P, Ludwig K, Mueser KT, Kane JM. Factor structure of therapist fidelity to individual resiliency training in the Recovery After an Initial Schizophrenia Episode Early Treatment Program. Early Intervention in Psychiatry. PMID 27860369 DOI: 10.1111/Eip.12409  0.089
2007 Gunduz-Bruce H, Narr KL, Gueorguieva R, Toga AW, Szeszko PR, Ashtari M, Robinson DG, Sevy S, Kane JM, Bilder RM. CSF sub-compartments in relation to plasma osmolality in healthy controls and in patients with first episode schizophrenia. Psychiatry Research. 155: 57-66. PMID 17398079 DOI: 10.1016/J.Pscychresns.2006.12.006  0.089
2015 Correli C, Skuban A, Ouyang J, Weiss C, Weiller E, Kane J. P.3.d.072 Efficacy and safety of brexpiprazole (OPC-34712) in acute schizophrenia: a pooled analysis of two pivotal studies European Neuropsychopharmacology. 25: S522-S523. DOI: 10.1016/S0924-977X(15)30720-3  0.089
1995 Szymanski S, Lieberman J, Pollack S, Munne R, Safferman A, Kane J, Kronig M, Cooper T. The dopamine-serotonin relationship in clozapine response. Psychopharmacology. 112: S85-9. PMID 7530378 DOI: 10.1007/BF02245011  0.088
2007 Lencz T, Lambert C, DeRosse P, Burdick KE, Morgan TV, Kane JM, Kucherlapati R, Malhotra AK. Runs of homozygosity reveal highly penetrant recessive loci in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America. 104: 19942-7. PMID 18077426 DOI: 10.1073/Pnas.0710021104  0.088
2016 Hagi K, Nosaka T, Pikalov A, Loebel A, Kane J. Safety of lurasidone in schizophrenia: a systematic review and meta-analysis of short-term trials utilizing active comparator European Neuropsychopharmacology. 26: S580-S581. DOI: 10.1016/S0924-977X(16)31643-1  0.088
2014 Shen JH, Zhao Y, Rosenzweig-Lipson S, Popp D, Williams JB, Giller E, Detke MJ, Kane JM. A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia. Journal of Psychiatric Research. 53: 14-22. PMID 24613032 DOI: 10.1016/j.jpsychires.2014.02.012  0.088
Hide low-probability matches.